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Table 1 Principal subroutines of regulated cell death 6 






























Dym  Mitochondrial membrane potential 
ACD  Accidental cell death 
AnnV  Annexin V 
APCs  Antigen presenting cells 
ATF6  Activating transcription factor 6 
BECN1  Beclin 1 
BMDCs Bone marrow-derived dendritic cells 
CICR  Ca2+-induced calcium release process 
CRT  Calreticulin 
CTLA-4 Cytotoxic T-Lymphocyte Antigen 4 
CTLs  Cytotoxic T lymphocytes 
DAMPs Damage-associated molecular patterns 
DCs  Dendritic cells 
ER  Endoplasmic reticulum 
ERAD  ER-associated degradation 
ETC   Electron transport chain 
FasL  Fas ligand 
HMGB1 High-mobility group box 1 protein 
ICD  Immunogenic cell death 
ICRP  IMMUNEPOTENT CRP 
IDO  Indoleamine 2,3-dioxygenase 
IMM  Inner mitochondrial membrane 
IP3  Inositol 1,4,5-trisphosphate 
IP3Rs  Inositol-1,4,5-trisphophate receptors 
JNK  Jun-N-terminal protein kinase 
MAMs  Mitochondrion-associated membranes 
MCU  Mitochondrial calcium uniporter 
MDSCa Myeloid-derived suppressor cells 
NCXs  Na+/Ca2+ exchangers 
OMM  Outer mitochondrial membrane 
PCD  Programmed cell death 
PD-1  Programmed cell death protein 1 
PE  Phycoerythrin 
PERK  Protein kinase RNA-like ER kinase  
PI  Propidium Iodide 
PIP2  Phosphatidylinositol l-4,5-bisphosphate 
PLC  Phospholipase C 
PMCA  Plasma-membrane Ca2+-ATPase 
PS  Phosphatidylserine 
PTP  Permeability transition pore 
RCD  Regulated cell death 
ROCs  Receptor-operated channels 
ROS  Reactive Oxygen Species 
RYRs  Ryanodine receptors 
SERCA Sarco(endo)plasmic reticulum Ca2+-ATPase 
SMOCs Second messenger-operated channels 
SOC  Store-operated channel 
SOCE  Store operated Ca2+entry 
TAAs  Tumor-associated antigens 
TCD  Tolerogenic cell death 
TCL  Tumor cell lysate 
TRAIL  TNF-related apoptosis-inducing ligand 
TRP  Transient receptor potential 
UPR  Unfolded protein response 
VDAC  Voltage-dependent anion channel 







Cancer recurrence is a serious problem in breast cancer patients, and immunogenic cell 
death (ICD) has been proposed as a strategy to overcome this handicap. 
IMMUNEPOTENT CRP (ICRP) acts as an immunomodulator and can be cytotoxic to 
cancer cells. Thus, the immunogenicity of ICRP-induced cell death was evaluated in 
breast cancer cells. This immunogenicity was evaluated in vitro, analyzing the principal 
biochemical characteristics of ICD in MCF-7 and 4T1 cells. Ex vivo, we assessed the 
ability of the tumor cell lysate (TCL) obtained from ICRP-treated 4T1 cells (ICRP-TCL) 
to induce DCs maturation, T-cell priming, and T-cell-mediated cancer cytotoxicity. In 
vivo, tumor establishment, tumor regression, and antitumor immune memory after 
prophylactic and therapeutic ICRP-TCL vaccinations in BALB/c mice was evaluated. 
ICRP induced an increase in cytoplasmic Ca2+ levels, which led to ROS overgeneration, 
loss of Dym, CRT exposure, and cell death. Moreover, ICRP treatment provoked 
autophagosome formation, eIF2α phosphorylation, and release of ATP and HMBG1 in 
breast cancer cells. Additionally, ICRP-TCL promoted DCs maturation, which triggered 
T cell-priming, that led to T cell-mediated cancer cytotoxicity. Prophylactic vaccination 
with ICRP-TCL prevented tumor establishment and induced long-term antitumor memory 
in BALB/c mice, involving DCs maturation in lymph nodes, CD8+ T-cells augmentation 
in peripheral blood, and ex vivo tumor-specific cytotoxicity by splenocytes. Finally, 
ICRP-TCL induced tumor regression in tumor-bearing mice, which also developed long-
term antitumor memory. In conclusion, ICRP induces ICD in breast cancer cells, leading 





La recurrencia es un serio problema en pacientes con cáncer de mama, y, la muerte celular 
inmunogénica (MCI) se ha propuesto como una estrategia para sobrepasar esta 
problemática. El IMMUNEPOTENT CRP (ICRP) actúa como inmunomodulador y es 
citotóxico en células de cáncer. Por lo tanto, se evaluó la inmunogenicidad de la muerte 
inducida por el ICRP en células de cáncer de mama. Para ello, in vitro, se estudiaron las 
principales características bioquímicas asociadas con la MCI en células MCF-7 y 4T1. Ex 
vivo, se evaluó la habilidad de el lisado tumoral (TCL) obtenido del tratamiento con ICRP 
a células 4T1 (ICRP-TCL) para inducir maduración de células dendríticas, estimulación 
de células T y citotoxicidad en células cancerosas. In vivo, se investigó el establecimiento 
tumoral, regresión tumoral y memoria antitumoral después de vacunaciones profilácticas 
y terapéuticas con ICRP-TCL. El ICRP incrementó los niveles de Ca2+ citoplasmático, 
desencadenando sobregeneración de ROS, perdida de Dym, exposición de CRT y muerte 
celular. Además, el ICRP provocó formación de autofagosomas, fosforilación de eIF2α y 
liberación de ATP y HMGB1. Por otro lado, el ICRP-TCL promovió la maduración de 
DCs, desencadenando una citotoxicidad dirigida hacia células cancerosas mediada por 
células T. La vacunación profiláctica con ICRP-TCL previno el establecimiento tumoral 
e indujo memoria antitumoral a largo plazo, la cual involucró maduración de DCs en 
ganglios linfáticos, aumento de células T CD8+ en sangre periférica y citoxicidad tumoral 
mediada por esplenocitos. Por último, el tratamiento con ICRP-TCL indujo regresión 
tumoral y memoria antitumoral a largo plazo. En conclusión, el ICRP induce MCI en 





One of the major homeostatic processes for maintenance of our bodies is phagocytosis of 
dying cells, this process dictates the immunological consequence that will be triggered, 
which can be tolerogenic, immunogenic, or silent (Green et al. 2009). In regard to cancer 
disease, malignant cells are prone to be overlooked by the immune system due to cancer 
immunoediting. In addition, several therapies and stress in tumor microenvironment 
trigger tolerogenic cell death, which provokes immune tolerance towards cancer cells, and 
a dim prognosis as a consequence. A strategy to turn cancer cells immunogenic is through 
the induction of immunogenic cell death (ICD), hence, the search for therapeutic regimens 
that render cancer cell death immunogenic and revert immune suppression is important 
(Kroemer et al. 2013). The bovine dialyzable leukocyte extract IMMUNEPOTENT CRP 
(ICRP) is cytotoxic to cancer cell lines and induces ICD in the murine melanoma model 
B16F10 (Rodríguez-Salazar et al. 2017), whereas in HeLa and MCF-7 cells ICRP induced 
reactive oxygen species (ROS)-dependent autophagosome formation (Alvarez-Valdez, 
2018). These are two of the major cellular process associated with ICD, suggesting that 
ICRP might induce ICD in other cancer models. Furthermore, endoplasmic reticulum 
(ER) stress, an early ICD biomarker, is associated with deregulation in Ca2+ signaling 
(Kepp et al. 2015), and previous studies in HeLa cells have demonstrated that ICRP 
induces calpain activation (Ca2+-dependent proteases) (Robles-Reyes 2011), however, 
Ca2+-implication in ICRP-mediated cell death is not entirely elucidated. Thus, the aim of 
this study was to understand the role of Ca2+ in ICRP-induced cell death and the 





1. CELL DEATH: THE PROCESS THAT RULES LIFE AND DISEASES 
 
“Death occurs so that life can happen and, paradoxically, the extinction of life is 
imperative for its continuation.” A.C. Martínez-Torres, Programed Cell Death…and Cancer, 2013. 
. 
It is estimated that one million cells die per second in our bodies in the course of normal 
tissue turnover, hence, cell death is one of the principal homeostatic processes and an 
essential part of life (Griffith and Ferguson 2011). A cell decides among three destinies: 
to divide, to specialize or to commit suicide. As it is expressed by the irreversibility of 
time, we undergo continuous changes every second, whereas cell death eliminates 
abnormal, infected, and unnecessary cells; cell division generates more cells, thus, these 
opposed processes work together to maintain the balance in multicellular organisms 
(Melino 2001). Notwithstanding, cell death is implicated in the pathogenesis of several 
diseases such as cancer, acquired immune deficiency syndrome (AIDS), Alzheimer’s 
disease, Parkinson’s disease and neurodegenerative diseases (Hotchkiss et al. 2009). In 
1991 was the first clear evidence of defects in the cell death machinery could lead to 
disease, when a mouse strain was serendipitously discovered, these animals showed a 
tendency to develop enlarged lymph nodes and spleen as well as autoimmune diseases. 
These organisms had mutations in the death receptor CD95 (Fas) and its ligand CD95 L 
(FasL), thus lymphocytes, which proliferated due to the exposure to an antigen, then failed 
to be eliminated at the end of the immune response because of the mutations that impair 
cell death pathways, causing T-cell accumulation, and triggering autoimmune diseases 
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(Cohen and Eisenberg 1991). Evidentially, the study of cell death is pivotal to understand 
diseases and to find new approaches of therapy. 
 
What is reality, the meaning of death? For a long time, it was difficult to define cell death, 
is ambitious to accomplish clear definitions of things that are shadows in Plato’s cave. 
Death and dying are events strongly influenced by culture and religion; hence, to decrease 
confusion in scientific community, the Editors of Cell Death and Differentiation have 
created the Nomenclature Committee on Cell Death (NCCD) where authors propose 
unified criteria for cell death. The NCCD propose that is important to discriminate 
between dying as a process and death as an end point. The cells that are succumbing to 
death are engaged in a process that is reversible until a first irreversible phase is trespassed, 
these “points-of-no-return” include massive protease activation, loss of ΔΨm, complete 
permeabilization of the mitochondrial outer membrane or exposure of phosphatidylserine 
(PS) that emit “eat me” signals for neighboring cells. Moreover, they suggests that a cell 
should be considered dead when any of the following criteria are met: (1) the cell has lost 
the integrity of the plasma membrane; (2) the cell including its nucleus has undergone 
complete fragmentation into discrete bodies; and/or (3) its corpse (or its fragments) have 
been engulfed by an adjacent cell in vivo. Furthermore, cells whose cell cycle is arrested 
would be considered as alive (Kroemer et al. 2009). 
 
Generally speaking, cell death can be classified as programed, regulated, and accidental 
cell death. Programmed cell death (PCD) stands for those physiological instances of cell 
death that occur in embryonic or post-embryonic development and tissue homeostasis. 
Regulated cell death (RCD) indicates cases of cell death (programmed or not) whose 
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initiation and/or execution is mediated by molecular machinery; thus, it can be inhibited 
by pharmacological and/or genetic manipulations. Finally, accidental cell death (ACD) 
refers to cell death triggered by physical conditions (e.g., freeze–thawing cycles, high 
concentrations of pro-oxidants), which cannot be inhibited by pharmacological and/or 
genetic interventions (Fig. 1) (Lorenzo Galluzzi et al. 2018). Henceforth, I will refer to 












Figure 1. Types of cell death. Regulated cell death can be influenced, at least to some extent, by specific 
pharmacologic or genetic interventions. The term programmed cell death is used to indicate regulated cell 
death instances that occur as part of a developmental program or to preserve physiologic tissue homeostasis. 
Accidental cell death refers to a type of cell death that occurs when cells are exposed to extreme physical, 
chemical or mechanical stimuli succumbing in a completely uncontrollable manner, reflecting the 
immediate loss of structural integrity. Adapted from Galluzzi et al. 2015. 
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Modulation of intracellular signaling is crucial for cell survival or death. Signaling for cell 
death can be activated after stimulation of death receptors, damage to cellular structures, 
deregulation of the system that controls ion movements across cell membranes or other 
stimuli. The major actors involved in the signaling pathway define the type of cell death 
that would be triggered.  
 
For instance, apoptotic cell death is determined by caspases (cysteine-dependent 
aspartate-directed proteases), while the autophagic machinery rules autophagic cell death. 
Moreover, executors of cell death may also participate in cell survival; for example, the 
activation of some caspases play a role in inflammation, proliferation and differentiation, 
also autophagosome formation is crucial for cell homeostasis through removal of damaged 
or unnecessary organelles (Galluzzi et al. 2018). Thus, it is thought that the decision of 
die or survive relies on the nature of the stimuli, and in the status of that particular cell. 
RCD-inhibitory and -promoting signals coexist and counteract each other, and at some 
stage one predominate over the other (Galluzzi et al. 2015). 
 
Is there more signaling for death or survival? Where the scales tip, will be the cell fate. 
For instance, in cancer disease there is a resistance to cell death typically acquired during 
tumorigenesis, thus in malignant cells RCD-inhibitory signals predominate over RCD-
promoting signals. The NCCD has also classified the different cell death modalities 
described until now, based on the molecular aspects that are essential for the process 
(Table 1).  However, it is important to mention that an interconnection can exist between 




Adapted from Galluzzi et al. 2018. 
 
Table 1. Principal subroutines of regulated cell death 
Cell death subroutines Definition 
Intrinsic apoptosis. 
Type of RCD initiated by perturbations of the extracellular or intracellular 
microenvironment, demarcated by MOMP (Mitochondrial Outer Membrane 
Permeabilization), and precipitated by executioner caspases, mainly caspase 
3. 
Extrinsic apoptosis. 
Specific variant of RCD initiated by perturbations of the extracellular 
microenvironment detected by plasma membrane receptors, propagated by 
caspase-8 and precipitated by executioner caspases, mainly caspase-3. 
Necroptosis. 
A modality of RCD triggered by perturbations of extracellular or intracellular 
homeostasis that critically depends on MLKL, RIPK3, and (at least in some 
settings) on the kinase activity of RIPK1. 
Ferroptosis. 
A form of RCD initiated by oxidative perturbations of the intracellular 
microenvironment that is under constitutive control by GPX4 and can be 
inhibited by iron chelators and lipophilic antioxidants. 
Pyroptosis. 
A type of RCD that critically depends on the formation of plasma membrane 
pores by members of the gasdermin protein family, often (but not always) as 
a consequence of inflammatory caspase activation mainly caspase 1. 
Parthanatos. 
A modality of RCD initiated by PARP1 hyperactivation and precipitated by 
the consequent bioenergetic catastrophe coupled to AIF-dependent and MIF-
dependent DNA degradation. 
Entotic cell death. 
A type of RCD that originates from actomyosin-dependent cell-in-cell 
internalization (entosis) and is executed by lysosomes. 
Lysosome-dependent 
cell death. 
A type of RCD demarcated by primary LMP and precipitated by cathepsins, 
with optional involvement of MOMP and caspases. 
Autophagy-dependent 
cell death. 
A form of RCD that mechanistically depends on the autophagic machinery 
(or components thereof). 
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2. Ca2+: THE JANIFORM KILLER 
 
“In the furnaces of the stars the elements evolved from hydrogen. When oxygen 
and neon captured successive α particles, the element calcium was born.” 
D. E. Clapham, Calcium Signaling, 2007. 
 
A long time ago, cells had to learn to adapt to changing environments, defying relentless 
entropy. Hence, cells must trigger signals through messengers whose levels vary over 
time; in this regard, Ca2+ is a highly versatile intracellular signal that regulates broad 
cellular functions and cell death. Ca2+ is not created from an enzymatic reaction or 
destroyed or converted into an inactive metabolite, thus, its functionality relies on 
variations in Ca2+ concentration in the cytosol and subcellular organelles, which is 
regulated by Ca2+ channels and pumps, and exchangers (Clapham 2007).  
 
Each cell type expresses a unique set of components from the Ca2+-signaling toolkit (Table 
2), however, the majority of Ca2+-signaling systems function by generating brief pulses of 
Ca2+. To trigger specific cellular outcomes, cells decode variations in Ca2+ levels; these 
signals can vary in magnitude as in spatial and temporal characteristics. For instance, 
localized increment in Ca2+ levels in cytosol can regulate cell migration, changes in the 
frequency and duration of cytosolic free Ca2+ oscillations may activate transcription 
factors, and large sustained increases in Ca2+ levels are associated with cell death 







Receptor-operated, voltage-sensitive and store-operated channels control the influx of 
Ca2+ into the cell, this influx is promoted when Ca2+ -permeable channels are open because 
of the level of free Ca2+ in most extracellular fluids (>1mM) is higher in comparison with 
the level of cytosolic free Ca2+ (~100nM), creating a concentration gradient. Once inside 
the cell, Ca2+ can interact with Ca2+-binding proteins or might be sequestered into cellular 
organelles such as the endoplasmic reticulum (ER) (the largest Ca2+ store in cells, reaching 
millimolar levels) or mitochondrion. Otherwise, the efflux of Ca2+ outside the cells 
requires energy, and it is mediated by the plasma-membrane Ca2+-ATPase (PMCA) or by 
the Na+/Ca2+-exchanger (NCX), which is electrogenic, exchanging three Na ions for one 
Ca2+ (Berridge, Bootman, and Roderick 2003; Monteith, Prevarskaya, and Roberts-
Thomson 2017). 
 
On the other hand, Ca2+ level in ER is regulated by sarco(endo)plasmic reticulum Ca2+-
ATPase (SERCA) pumps, which promotes the entry of Ca2+ into ER, whereas IP3 
receptors (IP3Rs) and ryanodine receptors (RYRs) controls Ca2+ efflux from ER. ER Ca2+ 
release is promoted by agonist stimulation through the generation of inositol 
1,4,5‑trisphosphate (IP3) through hydrolysis of phosphatidylinositol l-4,5-bisphosphate 
(PIP2) carried out by a phospholipase C (PLC). PLC has several isoforms, which are 
activated by distinct pathways, PLCβ is activated by G-protein coupled receptors, PLCγ 
is activated by tyrosine-kinase-coupled receptors, an increase in Ca2+ concentration 
activates PLCδ, and PLCε is activated through Ras. The dynamics of IP3 production varies 
depending on the PLC isoform that is activated. ER Ca2+ release can be also triggered by 
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calcium-induced calcium release process (CICR), whereby Ca2+ promotes its own release 
from ER. IP3Rs and RYRs are the principal Ca2+ channels that display CICR. IP3 dictates 
the sensitivity of IP3Rs to Ca2+. Also, Ca2+ directly activate RYRs, although cyclic ADP 
ribose can act as a sensitizer, thus, CICR is a process that amplifies microscopic initiation 
pulses into Ca2+ propagating signals (Monteith, Prevarskaya, and Roberts-Thomson 
2017). 
 
Another cellular organelle that has Ca2+-transporting proteins is the mitochondrion, these 
channels include the mitochondrial calcium uniporter (MCU) complex that take up Ca2+ 
electrophoretically inside the mitochondrion, and it can be released through three different 
pathways: reversal of the uniporter, Na+/H+-dependent Ca2+ exchange, or as a 
consequence of permeability transition pore (PTP) (Gómez-Suaga et al. 2018). Ca2+ can 
also interact with different Ca2+-binding proteins, which can function as Ca2+-effectors or 
Ca2+-buffers. Ca2+-effectors include troponin C, CaM, synaptotagmin, and the annexins, 
these proteins activate several Ca2+-sensitive cellular processes. Otherwise, Ca2+-buffers, 
such as calbindin D-28 (CB), and calretinin (CR), function to fine-tune the spatial and 
temporal properties of Ca2+ signals, altering the amplitude and recovery time of individual 
Ca2+ transients (Berridge, Bootman, and Roderick 2003). The components of Ca2+-
signaling system create diverse arrays of Ca2+ signals that can be different in spatial and 




Figure 2. Regulation of intracellular Ca2+ compartmentalization. Cellular Ca2+ import through the 
plasma membrane occurs by receptor-operated, voltage-sensitive and store-operated channels. Once inside 
the cell, Ca2+ can interact with Ca2+-binding proteins or be sequestered into the ER or mitochondrion. Ca2+ 
levels in the ER are affected by the relative distribution of SERCA pumps and IPP3Rs and RYRs, as well 
as by the relative abundance of Ca2+-binding proteins (calreticulin, calsequestrin) in the ER. The cytosolic 
Ca2+ concentration in unstimulated cells is kept at ~100 nM by both uptake into the ER and Ca2+ extrusion 
into the extracellular space by the PMCA. Ca2+efflux might also be mediated by the Na+/Ca2+ exchanger 
(NCX). ER Ca2+ release is triggered by agonist stimulation through the generation of IP3 through hydrolysis 
of PIP2 operated by a PLC. The mitochondrion takes up Ca2+ through a uniport transporter and can release 
it again through three different pathways: reversal of the uniporter, Na+/H+-dependent Ca2+ exchange, or as 




Table 2. Ca2+-signaling toolkit 
Receptors 
G-protein-coupled receptors: Muscarinic receptors, adrenoceptors, angiotensin receptor, 
endothelin receptors, metabotropic glutamate receptors, histamine receptor, oxytocin 
receptor (OT), extracellular Ca2+-sensing receptor (CaR), thrombin receptor (PAR1). 
Tyrosine-kinase-linked receptors: Platelet-derived growth factor receptors (PDGFRα, 
PDGFRβ), epidermal growth factor receptors. 
Transducers 
G proteins: Gqα, G11α, G14α, G16α, Gβγ 
Phospholipase C (PLC): PLCβ1–4, PLCγ1, PLCγ2, PLCδ1–4, PLCε, PLCζ. 
ADP ribosyl cyclase 
Channels 
Voltage-operated channels (VOCs): A plasma-membrane ion channel that is activated by 
membrane depolarization. 
Receptor-operated channels (ROCs): A plasma-membrane ion channel that opens in 
response to the binding of an extracellular ligand. MDA receptors (NR1, NR2A, NR2B, 
NR2C, NR2D), ATP receptor (P2X7), nACh receptor. 
Second messenger-operated channels (SMOCs): A plasma-membrane ion channel that 
 
opens in response to the binding of intracellular second messengers such as diacylglycerol, 
cyclic nucleotides or arachidonic acid. 
Store-operated channel (SOC): A plasma-membrane ion channel, that opens in response 
to the depletion of internal Ca2+ stores. 
Transient receptor potential (TRP) ion-channel family: Plasma-membrane ion channels. 
This family consists of three groups: the canonical TRPC family, the vanilloid TRPV 
family and the melastatin TRPM family. TRP channels tend to have low conductances and 
therefore can operate over much longer time scales without swamping the cell with too 
much Ca2+. 
Inositol-1,4,5-trisphophate receptors (IP3Rs): A Ca2+-release channel that is located in 
the membrane of the endoplasmic reticulum and is regulated by IP3 and Ca2+ itself. 
Ryanodine receptors (RYRs): A Ca2+-release channel that is located in the membrane of 
the endoplasmic reticulum and is regulated by several factors including Ca2+ itself, as well 




Na+/Ca2+ exchangers (NCXs): NCX1–3. Plasma-membrane enzyme that exchanges three 
moles of Na+ for one mole of Ca2+, either inward or outward, depending on the ionic 
gradients across the membrane. 
Mitochondrion channels and exchangers: permeability transition pore, Na+/Ca2+ 
exchanger, H+/Ca2+ exchanger, and Ca2+ uniporter, 
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Plasma membrane Ca2+-ATPases (PMCAs): PMCA1–4. A pump on the plasma 
membrane that couples ATP hydrolysis to the transport of Ca2+ from cytosolic to 
extracellular spaces. 
Sarco(endo)plasmic reticulum Ca2+-ATPases (SERCAs): SERCA1–3. A pump located 
in sarcoplasmic or endoplasmic reticulum membranes that couples ATP hydrolysis to the 
transport of Ca2+ from cytosolic to lumenal spaces. 
Golgi pumps: SPCA1, SPCA2. 
Ca2+-buffers 
Cytosolic buffers: calbindin D-28, calretinin, parvalbumin. 
ER buffers and chaperones: calnexin, calreticulin, calsequestrin, GRP 78 and 94 
Ca2+-
effectors 
Ca2+-binding proteins: calmodulin, troponin C, synaptotagmin, annexin I–X, neuronal 
Ca2+ sensor family, visinin-like proteins, hippocalcin, recoverin, guanylate-cyclase-
activating proteins. 
Adapted from Berridge et al., 2003; Monteith1 et al., 2017. 
 
Ca2+-signaling in cell death induction 
 
Although, Ca2+ is required for the functionality of cells, Ca2+ overload in the cell or 
perturbation of intracellular Ca2+ compartmentalization can trigger catastrophic events 




Ca2+ depletion in ER Ca2+ pool or Ca2+-overload in this organelle results in disturbances 
in protein folding and, as a consequence in ER stress. Under ER stress, the unfolded 
protein response (UPR) controls cell fate decisions (Kepp et al. 2015). The UPR acts to 
reduce unfolded protein load in ER through the attenuation of the influx of proteins into 
the ER, expansion of the ER membrane, and the synthesis of components of the protein 
folding and quality control machinery (Grootjans et al. 2016).  These cellular processes 
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are mediated by IRE1, ATF6 (activating transcription factor 6), and PERK (protein kinase 
RNA-like ER kinase) (Grootjans et al. 2016).  
 
In physiological conditions, the ER chaperone GRP78 binds to ATF6, IRE1 and PERK, 
staying inactive. Accumulation of unfolded proteins in the ER lumen in response to 
various stimuli competes with these molecular sensors for the binding of GRP78, resulting 
in ATF6, IRE1 and PERK derepression. After that, IRE1 suffer a dimerization, followed 
by autophosphorylation which triggers its RNase activity, this allows the degradation of 
certain mRNAs, and activation of the transcription factor XBP1s, which controls the 
transcription of genes encoding proteins involved in protein folding, ER-associated 
degradation (ERAD), protein quality control and phospholipid synthesis. ATF6 is 
normally localized in ER, but in UPR this factor is transported to the Golgi apparatus, 
where is processed and released in the cytosol as ATF6f, which controls genes encoding 
ERAD and XBP1. PERK is also activated after ER stress; PERK phosphorylates eIF2α 
(eukaryotic translation initiator factor 2α) to attenuate general protein synthesis, allowing 
the transcription of ATF4, a transcription factor that controls the transcription of genes 
associated with autophagy, cell death, and antioxidant responses (Fig. 3) (Hetz 2012; 
Kepp et al. 2015).  
 
Despite the fact that the UPR is activated to restore the homeostasis of the cells, ER stress 
can trigger cell death as a pis-aller mechanism. ER stress can trigger the activation of 
caspase-12 by m-calpain (Ca2+-activated cysteine protease), or through the formation of 
IRE1α-TRAF-2-pro-caspase-12 complex, which is formed as part of the UPR. Once 
activated, caspase-12 acts on effector caspases to generate cell death. It has also been 
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reported that IREα can activate the Jun-N-terminal protein kinase (JNK), which activates 
the proapoptotic Bcl-2 family member Bim, while inhibiting the antiapoptotic protein Bcl-
2 (Orrenius, Zhivotovsky, and Nicotera 2003).  
Figure 3. The unfolded protein response (UPR). In physiological conditions, GRP78 binds to, hence 
inhibiting, activating transcription ATF6, IRE1 and PERK. Unfolded proteins accumulating in the ER lumen 
in response to various stimuli compete with these molecular sensors for the binding of GRP78, resulting in 
their derepression. In these conditions, ATF6 is processed by the Golgi apparatus to generate an active 
transcription factor that activates several proteins involved in the maintenance of reticular homeostasis. 
IRE1 acquires both an endonucleolytic and a kinase activity, thereby becoming able to catalyze the 
alternative splicing of XBP1-coding mRNAs, the degradation of other mRNAs localized at the ER, and the 
phosphorylation of JNK1. Spliced XBP1 codes for a transcription factor that stimulates the synthesis of 
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proteins implicated in reticular protein handling. Phosphorylated JNK1 promotes autophagy by catalyzing 
the derepression of the essential autophagic factor beclin 1 (BECN1). PERK phosphorylates eIF2, hence 
preventing translation at standard start codons while facilitating the use of alternative open reading frames. 
This results in the post-transcriptional upregulation of ATF4. ATF4 initially promotes the synthesis of 
GRP78 and GADD34 (an eIF2 phosphatase), hence contributing to the re-establishment of homeostasis. If 
the protein unfolding-promoting stimulus persists, however, ATF4 (and ATF6) activate CHOP, hence 
favoring the transition between the adaptive and lethal phase of the ER stress response. Extracted from Kepp 
2015. 
 
Along with the UPR, Ca2+ depletion from ER Ca2+ pool activates the store operated Ca2+ 
entry (SOCE). When the stromal interaction molecules (STIM) (localized in the 
membrane of the ER away from the plasma membrane when ER Ca2+ stores are replete) 
detects Ca2+ depletion through the dissociation of Ca2+ from STIM, these proteins are 
aggregated and translocated to sections of the ER juxtaposed to the plasma membrane and 
binds Orai, which induces the opening of Orai-CRAC (calcium release activated Ca2+) 
channels (Fig. 4). This mechanism generates high concentrations of Ca2+ inside the cell, 
which can lead to alterations in plasma membrane potential, PS exposure through the 
activation of phospholipid scramblases, DNA degradation after the activation of Ca2+-
dependent enzymes, the activation of calpains that have a role in cell death, and the 
crosstalk between calpains and caspases. Moreover, mitochondrion can take up Ca2+ 
electrophoretically from the cytosol through a uniport transporter, a Ca2+ overload could 
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trigger disruptions in the homeostasis of this cellular organelle, and thus, cell death 
(Monteith, Prevarskaya, and Roberts-Thomson 2017). 
Figure 4. Store operated Ca2+entry. Activation of different types of receptors trigger PLC activation and 
Ca2+ release from the ER, which could lead to depletion of Ca2+ ER pool. This results in dissociation of Ca2+ 
from STIM, inducing its aggregation and conformational change (right). STIM then translocates to sections 
of the ER juxtaposed to the plasma membrane and binds Orai, resulting in the opening of Orai-CRAC 




The ER and mitochondrion association is the most studied and the first described inter-
organelle contact, the ER domain specialized in this association is known as 
mitochondrion-associated membranes (MAMs), these MAMs are defined as ER 
membranes that are in close apposition (10–50 nm) to the mitochondrion (Fig. 5) 
(Kerkhofs et al. 2017). Interactions between mitochondrion and MAMs of ER are 
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associated with different cellular functions, including inflammasome formation, calcium 
(Ca2+) signaling, mitochondrion and ER dynamics, autophagy and lipid biosynthesis 
(Gómez-Suaga et al. 2018).  
 
Ca2+ is one of the signals transferred between ER and mitochondrion at the MAMs, this 
association provide a Ca2+ micro-domain, where Ca2+ levels are higher than in the bulk 
cytosol, which is necessary to sustain ER–mitochondrion Ca2+ signaling (since the MCU 
has a low affinity for Ca2+). Once Ca2+ is released from ER, it can be transported across 
the outer mitochondrial membrane (OMM) via the high conductance voltage-dependent 
anion channel 1 (VDAC1), which is physically coupled to the IP3R through GRP75, then, 
Ca2+ can cross the inner mitochondrial membrane (IMM) via the mitochondrial Ca2+ 
uniporter (MCU), the poreforming unit in the MCU complex, consisting of MCU itself 













Figure 5. MAM components playing a role in ER-mitochondrial Ca2+ signaling. The principal 
components of the ER-mitochondrial Ca2+ exchange at the MAMs are the IP3R and VDAC1, which are 
physically coupled by the chaperone protein GRP75. When Ca2+ is released from the ER by the IP3R, it 
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freely permeates the OMM via VDAC1, to be transported to the mitochondrial matrix by the MCU, located 
in the IMM. The chaperone Sig-1R is able to modify IP3Rmediated Ca2+ signaling. Binding to GRP78 holds 
Sig-1R inactive, but under ER stress binding to GRP78 is disrupted and Sig-1R interacts with the IP3R, 
stabilizing the IP3R and enabling proficient Ca2+ signaling. The efficiency of Ca2+ exchange between ER 
and mitochondria is influenced by the presence and action of tethering proteins like PERK and Mfn2 and 
anti-tethering proteins like FATE1. Besides its function as a tethering protein, PACS-2 also contributes to 
MAM organization, while simultaneously having a role in the enrichment of the chaperone calnexin at the 
MAMs. Furthermore, calnexin is enriched at the MAMs by palmitoylation, a process that switches calnexin 
function from quality control/protein folding to ER Ca2+-signaling control by enhancing SERCA activity. 




The beauty and cruelty of existence is not something we can handle alone, this struggle 
extends beyond humans, and the entire organisms in earth compete and help one another. 
Two billion years ago, some cells evolve to use oxygen as energy source, then, a larger 
cell engulfed this oxygen-using cell, who survived inside its host, providing energy to the 
larger cell, these cells became depend one each other for survival. In eukaryote cells, that 
oxygen-using cell evolve into the mitochondrion, this organelle sequesters the toxic 
potential of components of the consumed cell, such as the electron-transport chain; for 
this reason, mitochondrial damage gives rise to signals that can kill the cell (Melino 2001).  
 
The oscillations of Ca2+ in the mitochondrion stimulate the mitochondrion’s metabolism, 
for instance, three enzymes that are regulated by Ca2+: pyruvate dehydrogenase, isocitrate 
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dehydrogenase, and α-ketoglutarate dehydrogenase are part of the TCA cycle. Moreover, 
Ca2+ stimulates the ATP synthase and complex III of the electron transport chain (ETC). 
In addition, Ca2+ influx into the mitochondrion’s matrix activates Ca2+-activated K+ 
channels and parallel H2O uptake in the mitochondrion, resulting in cristae compression 
and H2O2 extrusion, which stimulates IP3R activity (Kerkhofs et al. 2018; Orrenius, 
Zhivotovsky, and Nicotera 2003).  
 
However, Ca2+ overload results in opening of the mitochondrial permeability transition 
pore (mPTP), either by a direct action of Ca2+ on the mPTP or by Ca2+ binding to 
cardiolipin, thereby disrupting complex II of the ETC and subsequent ROS production. 
mPTP opening leads to mitochondrial swelling, rupture of the OMM, and release of pro-
apoptotic factors like cytochrome c and ultimately cell death (Fig. 6) (Kerkhofs et al. 
2018; Orrenius, Zhivotovsky, and Nicotera 2003). 
 
As I mentioned before, signals between cells and intracellular signals dictate the cell death 
modality that will be triggered, also the response to these signals is modulated by the 
particular components of the molecular machinery present on each cell. In some cells it 
has been demonstrated that the influx of Ca2+ from the extracellular space and the 
reduction of ER Ca2+ levels, leads to an ER stress that favors plasma membrane surface 
exposure of calreticulin (CRT) (Tufi et al. 2008). CRT exposure facilitates the uptake of 
dying cells by dendritic cells and the subsequent presentation of tumor-associated antigens 
to T lymphocytes, hence stimulating an immune response (Krysko et al. 2012). ER stress 
and Ca2+ fluxes has been proposed as common denominators of immunogenic cell death, 
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Figure 6. Ca2+ signaling at the ER and the mitochondrion in cell death and survival. Arrow-headed 
lines indicate a stimulatory or consequential effect. The release of Ca2+ from ER is mediated by the IP3R, 
gated by the intracellular messenger IP3. Ca2+ then travels via VDAC1, which is physically coupled to the 
IP3R through GRP75, and MCU to the mitochondrion matrix. Ca2+ oscillations targeted to the mitochondrion 
are able to stimulate mitochondrion’s metabolism in several ways. Extracted from Kerkhofs et al. 2018. 
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3. TOLEROGENIC AND IMMUNOGENIC CELL DEATH 
 
“I have abandoned the belief that the immune system's primary driving force is the need 
to discriminate between self and non-self. The immune system does not care about self 
and non-self, its primary driving force is the need to detect and protect against danger.” 
P. Matzinger, Tolerance, danger, and the extended family, 1994. 
 
The immune system is constantly exposed to dead cells; as part of life, mechanism must 
exist so that the immune system discriminates between several signals and decide the 
immunological consequences after cell death. These mechanisms participate in pathogens 
and cancer cells eradication, healing of tissues while avoiding responses to vital systems 
of the host. How does the immune system decide? In 2011 Griffith and Ferguson proposed 
the Five Ws of Dying Cells, saying that the nature of the immune response that develops 
in the face of dead cells depends on who dies, what it releases, when it dies, where it dies, 
and why it dies (Griffith and Ferguson 2011). In view of that, cell death can be tolerogenic, 
immunogenic, or “silent”. 
 
Tolerogenic cell death 
 
In a tissue context, phagocytosis of dying cells has a major role in avoiding toxic 
accumulation of cellular corpses and represents the final stage of cell death. During PCD, 
dying cells emit “find me” signals (e.g. CX3CL1) to recruit anti-inflammatory cells and 
ensure their efficient removal, they also release “keep-out” signals (e.g. lactoferrin) to 
avoid inflammatory cells. Moreover, among these soluble factors, dying cells present a 
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constellation of “eat me signals” on their surface, which acts on phagocytic receptors on 
immune cells to facilitating cellular engulfment, whereas living cells avoid phagocytic 
clearance through surface-associated “don´t eat me” signals (Garg et al. 2016). The best 
known tolerogenic “eat me” signal is phosphatidylserine (PS), which normally faces the 
inner lumen of the bilayered plasma membrane in living cells, however during cell death 
it becomes externalized on the outer leaflet of the plasma membrane owing to the 
coordinated activity of caspases and scramblases, and inactivation of flippases, this 
phospholipid binds to a large number of immune receptors in a phagocyte-type manner 
(Hankins et al. 2015; Nagata, Sakuragi, and Segawa 2020; Segawa and Nagata 2015). 
Along with PS exposure, externalized cardiolipin, oxidized low-density lipoproteins, 
thrombospondin, complement C1q and changes in membrane glycosylation status or 
charges also act as tolerogenic “eat me” signals (Garg et al. 2016). 
 
These tolerogenic “eat me” signals interact with antigen presenting cells (APCs) that 
exhibits immunosuppressive phenotypes, such as tolerogenic DCs, M2 MФ, N2 
neutrophils, myeloid-derived suppressor cells (MDSCs). As a consequence, APCs that 
performed tolerogenic phagocytosis do not achieve functional maturation, and present 
antigens to CD4+ T cells in absence of co-stimulatory signals such as CD80, CD86, CD40 
and CD83, and in presence of immunosuppressive cytokines like IL-10 or TGF-β, this 
promotes the differentiation of naive CD4+ T cells into inducible regulatory T (TReg) cells 
and T helper 2 (Th2) cells, which inhibit pro-inflammatory immune responses. TReg 
directly eliminate cytotoxic T lymphocytes (CTLs) through FasL or TNF-related 
apoptosis-inducing ligand (TRAIL) expression. Additionally, in this scenario CD8+ T 
cells are stimulated in the absence of activated CD4+ T cells, resulting in the 
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differentiation of helpless cytotoxic T lymphocytes (CTLs). Helpless CTLs has a short 
lifespan, and are able to secrete TRAIL which triggers cell death in CTLs and CD4+ T 
cells, resulting in tolerance (Garg et al. 2016; Green et al. 2009). 
 
Despite the fact that all dying cells can release damage-associated molecular patterns 
(DAMPs), the mechanism of cell death may modify these immunostimulatory molecules 
to promote tolerance instead of an immune response. For instance, ROS production can 
lead to the oxidation of a key cysteine residue in high-mobility group box 1 protein 
(HMGB1), neutralizing its ability to promote immune responses. Furthermore, some 
dying cells can release immunosuppressive mediators, such as interleukin-10 (IL-10), 
transforming growth factor-β (TGFβ), platelet-activating factor (PAF) and prostaglandin 
E2 (PGE2), or promote the release of these factors from the cell that engulfs them (Griffith 
and Ferguson 2011). 
 
Figure 7. Suggested mechanisms of tolerance induction by dying cells. Cells that undergo apoptosis can 
release DAMPs, such as HMGB1; however, ROS production during cell death may oxidize HMGB1, 
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thereby rendering it inactive. In addition, cytokines such as IL-10 and TGFβ can be released from dying 
cells, or alternatively, dying cells can stimulate macrophages to release these molecules as well as PAF and  
PGE2. Production of these cytokines induces the differentiation of naive CD4+ T cells into TReg cells and 
Th2 cells, which inhibit pro-inflammatory immune responses. Simultaneously, CD8+ T cells are stimulated 
in the absence of activated CD4+ T cells, resulting in the differentiation of helpless cytotoxic T lymphocytes 
(CTLs). The cells can function in a primary cytotoxic response but produce the death ligand TRAIL 
following secondary exposure to antigen. TRAIL triggers apoptosis of the helpless CTLs and other activated 
CD4+ T cells, resulting in tolerance. Extracted from Green et al. 2009. 
 
Immunogenic cell death 
 
Immunogenic cell death (ICD) is a cell death modality that does stimulate an immune 
response against dead-cell antigens. The ability of RCD to drive adaptive immunity relies 
on two major parameters: antigenicity and adjuvanticity. Antigenicity is conferred by the 
expression and presentation of antigens that fail to induce clonal deletion in the context of 
central tolerance in a specific host, implying that the host contains naïve T cell clones that 
can recognize such antigens, hence, normally, healthy cells are limited in their ability to 
drive ICD, as their antigens are typically expressed by the thymic epithelium during T cell 
development. Adjuvanticity is provided by the spatiotemporally coordinated release or 
exposure of danger signals that are necessary for the recruitment and maturation of APCs, 
which are cumulatively referred to as damage-associated molecular patterns (DAMPs); 
whereas most of these molecules exert non-immunological functions inside the cell, their 
exposure on the cell surface or their secretion in the extracellular space as a result of 
cellular stress can function as danger signals for the immune system. Exposure of 
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calreticulin (CRT), and the release of ATP and HMGB1 are the principal DAMPs 
associated with ICD (Kroemer et al. 2013). 
 
Different cell death modalities imply a release of ATP, this extracellular ATP is a well-
known “find me” signal for macrophage and dendritic cells (DCs), upon its binding to 
P2Y2 receptors (widely expressed on cells from the myeloid lineage) (Elliott et al. 2009). 
Furthermore, it has been demonstrated that ATP stimulates bone marrow–derived DCs 
maturation with an increase in the expression of CD40, CD80, CD83, and CD86 (Wilkin 
et al. 2001). Moreover ATP-P2RX7 ligation leads to the activation of the inflammasome, 
which stimulates the proteolytic maturation of pro-inflammatory cytokines, mainly IL-1β 
and IL-18, and their subsequent release into the extracellular space. As a consequence, IL-
1β promotes the functional polarization of IFN-γ-secreting cytotoxic T lymphocytes 
(CTLs), which are the principal players in the cell-mediated immune response 
(Ghiringhelli et al. 2009).  
 
Otherwise, cells succumbing to ICD present an array of surface-exposed “eat me” signals, 
such as CRT or HSP90. Interaction of these “eat me” signals with phagocytic receptors 
on immune cells (e.g. LRP1) aids to remove the cells undergoing ICD (Obeid et al. 2007). 
Moreover, it has been demonstrated that CRT elicits the production of pro-inflammatory 
cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) from DCs, 
thereby facilitating Th1 and/or Th17 polarization. Similarly, HSP90 binding on immune 
cells facilitates DC maturation and Th1/17 priming (Garg et al. 2016).  
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HMGB1 is another example of DAMP that can be released by cells succumbing ICD, it 
has been demonstrated that HMGB1 binds to TLR4, activating the release of pro-
inflammatory cytokines by monocytes/macrophages, also, when it is associated with 
CXCL12 it can mediate mononuclear cells’ recruitment. In DCs, HMGB1 increase the 
expression of pro-IL-1β and avoids the lysosomal degradation of engulfed tumor antigens, 
which is a major prerequisite for efficient cross-presentation (Guido Kroemer et al. 2013; 
Krysko et al. 2012). 
 
As a consequence, APCs that carried out immunogenic phagocytosis are able to present 
the antigens to CD4+ T cells in presence of co-stimulatory molecules and pro-
inflammatory cytokines, such as IL-6, IL-12, IL-1β, promoting the differentiation of Th1 
cells who orchestrate a type-1 immunity consisting of IFN-γ-driven antigen-directed 
cytostatic effects and suppression of TReg differentiation. Also, these APCs stimulate the 
cross-talk between Th1 cells and CTLs and thereby facilitating CTL-elicited cell 
elimination through IFN-γ, FasL-CD95 interaction and perforin-granzyme action (Green 
et al. 2009). 
 
Molecular mechanisms behind Immunogenic cell death 
 
The kinetics and intensity of DAMPs release are dictated by intracellular responses driven 
by the initiating stressor. Overgeneration of ROS, ER stress, and autophagosome 
formation are mechanisms that activate danger-signaling pathways, which stimulate the 
exposure/release of DAMPs. It has been demonstrated that ROS may be crucial for cell 
death-immunogenicity as this was diminished in the presence of antioxidants (Panaretakis 
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et al. 2009). Moreover, it is proposed that simultaneous presence of ER stress and ROS 
production increase the number of DAMPs emitted (Krysko et al. 2012; Martins et al. 
2011). Nevertheless, the stress in the ER has been observed in almost all scenarios of ICD 
described so far. It has been demonstrated that several ICD inductors compromise cells 
with an intense ER stress which involves an overgeneration of ROS, increased 
cytoplasmic Ca2+ concentrations, and PERK activation. It has been observed that CRT 
translocation process requires the activation of PERK (Luo and Lee 2013), and as I 
mentioned before, activated PERK phosphorylates eIF2α (P-eIF2α), which has been 
established as an early ICD biomarker. P-eIF2α stimulates translational activity of ATF4 
that regulates expression of autophagy-associated genes, such as Atg5, Atg7, and Atg10 
(Kepp et al. 2013). 
 
In addition, ER stress triggers JNK1 phosphorylation by IRE1α, which promotes 
autophagy by catalyzing the derepression of the essential autophagic factor beclin 1 (Fig. 
3) (Kepp et al. 2013; Kroemer et al. 2013). Moreover, autophagic vesicles loaded with 
ATP can fusion with the plasma membrane to release this nucleotide into the extracellular 
medium upon autophagy stimulation in a V-SNARE-dependent manner (Fader, Aguilera, 
and Colombo 2012). 
 
ICD has been taking great importance in regard to cancer therapy, preclinical and clinical 
data support the idea that the way in which cancer cells succumb to cell death in response 
to treatment may be far more important for long-term disease outcome, than the fraction 
of cells that die. Some scientists believe that, as cancer therapies are unable to eradicate 
100% of cancer cells, which is an utopian goal, the efforts in cancer research should 
 28	
concentrate on the development of combinational therapeutic regimens that render cancer 
cell death immunogenic and revert immune exhaustion or suppression. 
Figure 8. Immunogenic cell death (ICD). In the course of ICD, the cell may suffer deregulation in Ca2+ 
homeostasis that can lead to loss of mitochondrial membrane potential and overgeneration of ROS. This 
could generate an ER stress, triggering CRT exposure, eIF2α phosphorylation and autophagosome 
formation. These danger-signaling pathways lead to alterations in the composition of the plasma membrane 
of dying cells (CRT exposure), as well in their microenvironment (release of ATP and HMGB1), which 
stimulate DCs maturation. These DCs can then prime CD4+ and CD8+ T cells and thereby trigger 
immunogenic T helper 1 (Th1) cell and cytotoxic T lymphocyte (CTL) responses, respectively, promoting 
an immune response against dead-cell antigens. 
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4. CANCER: THE DISEASE THAT DESTROYS THE HOST WHO 
NOURISHES IT. 
 
“If prayers are heard in Heaven, this prayer is heard the most: Dear God, please, not 
cancer. We lack only the will and the kind of money and comprehensive planning that 
went into putting a man on the moon.” Citizens Committee for the conquest of Cancer, Mr. Nixon 
you can cure cancer, 1969. 
 
Cancer is one of most important unsolved problems we have in medicine, this word 
encloses a group of diseases that start in almost any tissue of the body when abnormal 
cells grow uncontrollably, go beyond their usual boundaries to invade adjoining parts of 
the tissue and/or spread to other organs, this process is called metastasizing and is a major 
cause of death from cancer. Cancer is the second leading cause of death globally, 
accounting for an estimated one in six deaths, in 2018. Lung, prostate, colorectal, stomach 
and liver cancer are the most common types of cancer in men, whereas breast, colorectal, 
lung, cervical and thyroid cancer are the most common among women (WHO 2020). 
 
Besides its heterogeneity, all cancer diseases share these hallmarks: cell death resistance, 
deregulation in cellular energetics, sustaining proliferative signaling, growth suppressor 
evasion, avoidance of immune destruction, replicative immortality, tumor-promoting 
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inflammation, activation of metastasis and invasion, angiogenesis induction, and genome 




Breast cancer is the most common malignancy and the leading cause of cancer-related 
death in women worldwide (Fig. 9) (WHO 2020). On the molecular level, breast cancer 
is a heterogeneous disease, including molecular features such as expression of human 
epidermal growth factor receptor 2 (HER2), expression of hormone receptors (estrogen 
receptor and progesterone receptor) and/or BRCA mutations. The classification of Perou 
and Sorlie in 2000, proposed four subtypes of breast cancer: luminal A and luminal B 
(expressing hormone receptors), basal-like and HER2-enriched (without hormone 
receptor expression), and treatment strategies differ according to molecular subtype (Dai 
et al. 2016). 
 
One of the principal pitfalls leading to the mortality of breast cancer is associated with 
distant metastasis and its ability to recur up to 20 years after diagnosis (Fig. 10), whereas 
localized disease is curable in ~60–80% of patients with early-stage, metastatic or 
recurrent disease carries a dismal prognosis (Richman and Dowsett 2019). This scenario 
is related to the low immunogenicity of breast cancer cells, as a result of cancer cell release 
of immune-suppressive factors, which block the cancer-immunity cycle (Gatti-Mays et al. 
2019). However, it is now being proposed that with appropriate immune response 
stimulation, any cancer cell could be turn immunogenic. It has been reported that breast 
cancer patients treated with anthracyclines (ICD inducers) showed an increment in the 
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ratio of CD8+ T cells over regulatory T cells intratumorally, and this predict a favorable 
therapeutic response (Ladoire et al. 2011). 
 
 





Figure 10. Outcomes of women with ER-positive breast cancer. Out of ~46,000 women diagnosed with 
ER+ breast cancer annually, ~60% will be cured with surgery alone (part a), and ~40% will have residual 
micrometastatic disease after surgery (part b). The majority of these women will be treated with endocrine 
therapy and might subsequently have a complete response (part c), no response (part d), which can lead to 
metastatic outgrowth (part e) within a short period of time, or a partial response (part f). A partial response 
would be associated with the presence of residual micrometastatic disease, which would either acquire 
resistance leading to early recurrence (part g) or enter into a dormant state (part h). Dormant micrometastatic 
disease (part i) can be maintained, a process that can continue beyond 5 years (part j) or exit from dormancy 
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can occur within 5 years (part k) or beyond 5 years (part l). The percentages given after 5 years are for the 
population of women with micrometastatic disease after surgery and not the overall population. *Sometimes 
preceded by adjuvant radiotherapy and/or chemotherapy. Extracted from Richman and Dowsett 2019. 
 
5. RETURNING CANCER CELLS TO THEIR IMMUNITY CYCLE 




In 1891 oncology met immunology when William B. Coley, a renowned surgeon at 
Memorial Hospital in New York, noticed that cancer patients who got infections after 
surgery seemed to do better than people who didn't get an infection, thus he tried 
immunomodulating therapy for cancer with the use of erysipelas in a patient with 
inoperable sarcoma: Signor Zola, who survived another 8 years after being treated by 
Coley (Coley 1991). He then created a filtered mixture of bacterial lysates called “Coley’s 
Toxins” to treat tumors, his first patient named John Ficken with a large inoperable tumor 
(likely a malignant sarcoma) had a complete remission, lasting until his death 26 years 
later of a heart attack. Some reports indicate that of 186 patients, in 105 (57%), the 
treatment was regarded as successful (of these, 35 tumors were operable and 70 tumors 
were primarily inoperable, 2 of which were treated with apparent success with 
radiotherapy), today, it is believe that Coley’s Toxins may boost the immune system to 
attack cancer cells. However, clinical interest diminished in favor of radiotherapy and 
chemotherapy, which promised a breakthrough in cancer treatment (Kienle 2012; 
Richardson et al. 1999; Wiemann and Starnes 1994).                                                                                                   
 34	
Sixteen years later, Paul Ehrlich proposes that the immune system usually suppresses 
tumor formation, a concept that becomes known as the “immune surveillance” hypothesis 
(Ehrlich 1909), later confirmed by Robert Schreiber, Lloyd Old, and others in the first 
decade of the third millennium (Shankaran et al. 2001; Smyth, Thia, Street, Cretney, et al. 
2000; Smyth, Thia, Street, MacGregor, et al. 2000). This allowed to define the Cancer-
Immunity Cycle concept, which implies that tumor-associated antigens, accompanied by 
danger signals, are released by cancer cells and then captured by dendritic cells (DCs) for 
processing, promoting their efficient immunocompetence against cancer (Fig. 11) (Chen 
and Mellman 2013). 
Figure 11. The Cancer-Immunity Cycle. In the first step, neoantigens created by oncogenesis are released 
and captured by dendritic cells (DCs) for processing (step 1). Next, DCs present the captured antigens on 
MHCI and MHCII molecules to T cells (step 2), resulting in the priming and activation of effector T cell 
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responses against the cancer-specific antigens (step 3). The nature of the immune response is determined at 
this stage, with a critical balance representing the ratio of T effector cells versus T regulatory cells being 
key to the final outcome. Finally, the activated effector T cells traffic to (step 4) and infiltrate the tumor bed 
(step 5), specifically recognize and bind to cancer cells through the interaction between its T cell receptor 
(TCR) and its cognate antigen bound to MHCI (step 6), and kill their target cancer cell (step 7). Killing of 
the cancer cell releases additional tumor-associated antigens (step 1 again) to increase the breadth and depth 
of the response in subsequent revolutions of the cycle. Each step of the Cancer-Immunity Cycle requires the 
coordination of numerous factors, both stimulatory and inhibitory in nature. Stimulatory factors shown in 
green promote immunity, whereas inhibitors shown in red help keep the process in check and reduce 
immune activity and/or prevent autoimmunity. Extracted from Chen and Mellman 2013. 
 
Despite the fact that cancer immunosurveillance challenges cells that have undergone 
neoplastic transformation, the most immunoevasive or highly mutagenic cancer cells are 
able to escape immunosurveillance and generate a clinically relevant tumor. Thus, cancer 
cells within an established tumor are able to resist anti-tumor immunity. Along with 
immunosuppressive microenvironment within the tumor, cancer cells directly employ a 
number of mechanisms for immunoevasion, such as acquaintance of low immunogenicity 
by downregulating tumor-associated antigens (TAAs) and MHC class I expression, 
inciting tolerance by suppressing CD4+/CD8+T cells via immunosuppressive cytokines 
(e.g. IL-10 or TGFβ) or immune-checkpoints (e.g. programmed cell death 1, programmed 
cell death-ligand 1, cytotoxic T lymphocyte-associated protein-4), and resisting immune 
cell-mediated lysis by blunting cell death pathways. Thus, apart from therapies involving 
direct stimulation of innate or adaptive immune cells, cancer cells are also required to be 
made immunogenic (Garg and Agostinis 2017; Garg, Dudek, and Agostinis 2013). 
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Immunological responses triggered by anti-cancer therapy-induced cell death 
 
Induction of cell death by pharmacological means is the basis of almost every non-
invasive cancer therapy. Anti-cancer therapy-induced cancer cell death can be subdivided 
into three distinct profiles: tolerogenic cell death (TCD), immunogenic cell death (ICD), 
and inflammatory cell death. TCD elicits induction of tolerogenicity by suppressing anti-
cancer immunity through the release of anti-inflammatory factors. ICD elicits production 
of pro-inflammatory cytokines due to co-stimulation conveyed by DAMPs, resulting in 
immunostimulatory phagocytosis of cancer cell-corpses. Inflammatory cell death elicits 
acute phase response and other such innate inflammatory reactions that are composed of 
some tolerogenic and immunogenic signals that create ambiguous immune responses. As 
I as mentioned earlier, TCD suppress DC activity thereby reducing the possibility of 
CD4+/CD8+ T-cell activation in general, thereby, it is not surprising that TCD-inducing 
anticancer therapies (e.g. etoposide, cisplatin, docetaxel or mitomycin C) facilitates 
accumulation of immunosuppressive immune cells such as M2 MФ, MDSCs, Th2 cells, 
and TReg cells within the tumor. Otherwise, ICD has received high attention because the 
exposure of cancer cells to ICD inducers (e.g. anthracyclines, cyclophosphamide, 
oxaliplatin) is (in most cases) adequate for the activation of robust anti-tumor immunity 
(Fig. 12) (Dudek et al. 2013; Garg and Agostinis 2017; Zhou et al. 2019).  
 
Therefore, therapeutic success in cancer patients involves an ICD inducer, the response to 
the immunogenic signals triggered by the ICD, and tumor infiltration by immune 
effectors, which return cancer cells to the Cancer-Immunity Cycle (Fig. 11) (Zitvogel, 
Kepp, and Kroemer 2011). Several studies indicate that ICD is a hopeful strategy to 
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convert cancer cells into their own vaccine, promising a long-term success of anticancer 
therapies (Li 2017). 
 
Figure 12. Immunological responses triggered by anti-cancer therapy-induced cell death. 
Immunological profiles of tolerogenic cell death (TCD) and immunogenic cell death (ICD), and their 
consequences for anti-tumor immunity or tolerance toward tumor. 
 
Nonetheless, due to the complexity of cancer diseases, ICD may not succeed, because of 
immunotherapy-resistance mechanisms, such as low presence of tumor-infiltrating 
lymphocytes (TILs), T-cell anergy or exhaustion, enrichment of the tumor with 
immunosuppressive factors or immune-checkpoints, low MHC-I expression, 
unresponsiveness to IFNs, and low burden of TAAs. In addition, resistance mechanisms 
that directly inactivate immunogenic signaling can also form a hurdle, these mechanisms 
include mutations in pattern recognition receptors (PRRs), mutations or ablation of 
proteins mediating danger signaling, and disruption of immunogenic phagocytosis (e.g. 
by downregulating endogenous levels of CRT) (O’Donnell, Teng, and Smyth 2019). 
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Hence, it is important to overcome such resistance mechanisms via combinatorial 
regimens, for an efficient exploitation of ICD in cancer therapy (Fig. 13). Moreover, 
chemotherapy and radiation are often administered to patients at high doses, which has 
been associated with immunosuppressive rather than immunostimulatory effects, thereby, 
in these scenarios cancer cell death is prone to be overlooked by the immune system or to 
stimulate immune tolerance (Baskar et al. 2012; Zitvogel, Kepp, and Kroemer 2011), 
hence, the discovery of novel and efficient ICD inducers needs prioritization in cancer 
research. 
Figure 13. Combinatorial regimens and immunological profiles. Schematic representation of how 
different immunological profiles of anti-cancer therapy-induced cell death can be exploited for designing 
highly efficacious cancer immunotherapy regimens. Extracted from Garg and Agostinis 2017. 
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6. THE BOVINE DIALIZABLE LEUKOCYTE EXTRACT, 
IMMUNEPOTENT CRP, AS AN IMMUNOGENIC CELL DEATH 
INDUCER 
 
IMMUNEPOTENT CRP (ICRP) is a bovine dialyzable leukocyte extract (DLE) obtained 
from disrupted spleen. ICRP is a mixture of substances with biological activity, which 
provides several applications in human health. Nowadays ICRP has demonstrated to exert 
immunomodulatory as well as anti-cancer functions that I will further describe.  
 
As for immunomodulatory activities, ICRP improved survival (90%) in BALB/c mice 
with LPS-induced endotoxic shock, decreasing IL-10, IL-6, and TNF-α levels in serum 
(Franco-Molina et al. 2004). In addition, ICRP decreased NO, TNF-α and IL-6 but 
increased IL-10 production in LPS-stimulated murine peritoneal macrophages (Franco-
Molina et al. 2005). Moreover, in LPS-stimulated human macrophages ICRP increased 
endogenous antioxidants activity (catalase, glutathione peroxidase, and superoxide 
dismutase), and decreased cyclooxygenase-2 activity, PGD2, NO, and TNF-α production 
(Franco-Molina et al. 2011). Furthermore, in lung and breast cancer patients undergoing 
chemotherapy or/and radiation therapy, ICRP administration resulted in improved life-
quality and immunomodulatory activity (increasing the total leukocytes and T-
lymphocyte subpopulations) (Franco-Molina et al. 2008; Lara et al. 2010). 
 
In regard to anti-cancer proprieties, ICRP induced loss of cell viability in breast (MCF-7, 
BT-474, MDA-MB-453), lung (A549, A427, Calu-1, INER-51), cervical (HeLa, SiHa), 
and lymphoid (L5178Y, K562, MOLT-3) cancer cell lines, without affecting the viability 
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of human monocytes and PBMCs, and murine peritoneal macrophages (Franco-Molina et 
al. 2006; Martinez-Torres et al. 2019; Martínez-Torres et al. 2018; Sierra-Rivera et al. 
2016).  
 
In cervical and lung cancer cell lines, ICRP triggered caspase-independent cell death 
relying on ROS production, which involves cycle arrest, DNA degradation, and 
mitochondrial damage (Martinez-Torres et al. 2019; Martínez-Torres et al. 2018). In 
murine melanoma, ICRP decreased the viability of B16F10 cells, which involves an 
activation of caspase-3, also, ICRP-treatment decreased tumor weight and improved the 
survival of tumor-bearing mice, showing a decrease in VEGF production and prevention 
of metastasis (Franco-Molina et al. 2010), moreover, ICRP combined with oxaliplatin 
increased DAMPs release and the rate of ICD (Rodríguez-Salazar et al. 2017).  
 
In breast cancer cells, ICRP induced caspase-independent, ROS-dependent cell death and 
ROS-dependent autophagosome formation (Alvarez-Valdez, 2018); furthermore, breast 
tumor-bearing mice treated with ICRP present a decrease in tumor volume and increase 
in survival in comparison with untreated mice. Also, within the tumor, ICRP treatment 
decreased PD-L1, IDO and Gal-3 expression, IL-6, IL-10, and MCP-1 levels, and 
increased IFN-γ, and IL-12 levels. Moreover, ICRP treatment increase CD8+ T cells, 
memory T cells, and innate effector cells in peripheral blood, where they also observed an 
increase in IFN-γ, and IL-12 levels (Santana-Krímskaya et al. 2020). These results 




Breast cancer is the most frequently diagnosed cancer and the leading cause of deaths in 
women. One of the principal pitfalls leading to the mortality of this disease is associated 
with distant metastasis and its ability to recur up to 20 years after diagnosis, these 
characteristics are related with the low immunogenicity of breast cancer cells, as a result 
of cancer cell release of immune-suppressive factors, which block the cancer-immunity 
cycle. However, it is now being proposed that with appropriate immune response 
stimulation, cancer cells could be turn immunogenic. In this regard, several studies 
indicate that immunogenic cell death (ICD) is a hopeful strategy to convert cancer cells 
into their own vaccine, promising long-term success of anticancer therapies relying on 
memory immune response induction, which could deal against high recurrence rate in 
breast cancer patients. IMMUNEPOTENT CRP (ICRP) is cytotoxic to several cancer cell 
lines, and induces ICD in the murine melanoma model B16F10, whereas in MCF-7 and 
HeLa cells, ICRP-mediated cell death involves reactive oxygen species (ROS)-dependent 
autophagosome formation, and loss of mitochondrial membrane potential, which could be 
associated with deregulations in Ca2+ homeostasis. Ca2+ fluxes, overgeneration of ROS, 
and autophagy stimulate intracellular danger signaling pathways that regulate the release 
of DAMPs and thus, ICD. These results strongly suggest that ICRP might induce ICD in 
other cancer models, as a conserved mechanism. The aim of this study was to investigate 
the immunogenicity of ICRP-induced cell death in a breast cancer model as well as the 
role of Ca2+ in this mechanism, using human and murine cell lines, as well as, ex vivo and 





IMMUNEPOTENT CRP induces Ca2+-dependent cell death on breast cancer cells, which 








To evaluate the role of Ca2+ and the immunogenicity of IMMUNEPOTENT CRP-induced 
cell death on breast cancer. 
 
Specific objectives: 
To investigate the implication of Ca2+ in the mechanism regulating ICRP-induced cell 
death on breast cancer cells through: 
• The analysis of the capacity of ICRP to induce an increase in cytoplasmic Ca2+ levels 
on breast cancer cells. 
• The characterization of Ca2+-dependence in the regulated cell death, ROS production, 
loss of mitochondrial membrane potential, and calreticulin exposure mediated by 
ICRP on breast cancer cells. 
To evidence the immunogenicity of ICRP-mediated cell death in a breast cancer model 
through: 
• The in vitro assessment of the principal biochemical characteristics of immunogenic 
cell death caused by ICRP treatment on breast cancer cells. 
• The ex vivo evaluation of the capacity of ICRP-induced cell death to stimulate 
dendritic cell maturation, which triggers an immunocompetence of T cells against 
cancer cells. 
• The in vivo demonstration of an antitumor immune response generated by prophylactic 
and therapeutic vaccinations with tumor cell lysate (TCL) obtained from ICRP-treated 
4T1 cells (ICRP-TCL).  
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VI. MATERIALS AND METHODS 
 
Cell culture 
MCF-7 human breast adenocarcinoma (ATCC® HTB-22TM) and 4T1 murine mammary 
adenocarcinoma (ATCC® CRL2539TM) cell lines were obtained from the American 
Type Culture Collection. MCF-7 cells were cultured in DMEM-F12 supplemented with 
10 % fetal bovine serum (FBS) and 1 % penicillin-streptomycin (complete DMEM), and 
4T1 cells were cultured in RPMI-1640 supplemented with 10 % FBS and 1 % penicillin-
streptomycin (complete RPMI) (Life Technologies, Grand Island, NY) and routinely 
grown in plastic tissue-culture dishes (Life Sciences, Corning, NY). All cell cultures were 
maintained in a humidified incubator in 5 % CO2 at 37 °C. Cell count was performed in a 
Neubauer chamber, using 0.4% trypan blue (MERCK, Darmstadt, Germany). 
 
Animals 
The Animal Research and Welfare Ethics Committee (CEIBA), of the School of 
Biological Sciences approved this study: CEIBA-2019-006. All experiments were 
conducted according to Mexican regulation NOM-062-ZOO-1999. Female BALB/c mice 
(Six-to-eight-week-old; 20 ±2 g weight) were provided by the animal house at the 
Universidad Autonoma de Nuevo Leon, Mexico. Animals were housed in plastic cages 
and given seven days to acclimate to the housing facility. Environmental conditions were 
temperature 21°C ±3°C, humidity 55% ±10%, and 12 h light/dark cycle. Animals were 
supplied with rodent maintenance food (LabDiet, St. Louis, MO) and water ad libitum, 
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and they were monitored twice daily for health status, no adverse events were observed. 
Mice were randomly assigned to different groups for all studies. 
 
Intracellular Ca2+ levels analysis 
For this assay, 5x105 cells were plated in 6-well dishes (Life Sciences) in complete 
DMEM or RMPI to a final volume of 2 mL and incubated with ICRP CC50 for 18 h 
(MERCK). Then, cells were washed twice with KREBS buffer, suspended in RINGER 
buffer with 0.001 µg/mL of Fluo-4 AM (Life Technologies) and 0.001 µg/mL of Pluronic 
F-127 (Life Technologies), and incubated at 37 °C for 30 min. Next, cells were washed 
twice with RINGER buffer assessed by confocal microscopy (Olympus X70). For flow 
cytometry assays, 5x104 cells/well in 24-well dishes (Life Sciences) were incubated with 
ICRP CC50 for 18 h (MERCK) in complete DMEM or RPMI to a final volume of 400 μL. 
Cells were then detached, washed with KREBS buffer, and suspended in 200 μL of 
RINGER buffer with 0.001 µg/mL of Fluo-4 AM (Life Technologies) and 0.001 µg/mL 
of Pluronic F-127 (Life Technologies), and incubated at 37 °C for 30 min. Cells were then 
washed with RINGER buffer and assessed by BD Accury C6 flow cytometer (Becton 
Dickinson, Franklin Lakes, NJ). Results were analyzed using FlowJo Software (LLC, 
Ashland, OR). 
 
Cell death assay 
Cell death was measured using 1 µg/mL APC Annexin V (BD Pharmingen, San Jose, CA) 
and 0.5 µg/mL propidium iodide (PI) (MERCK). In brief, 5x104 cells/well in 24-well 
dishes (Life Sciences) were incubated with different doses of ICRP for 24 h to stablish 
ICRP CC50 or ICRP. CC50  for 24 h in presence or absence of 1.5 mM BAPTA (MERCK) 
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in complete DMEM or RPMI to a final volume of 400 μL. Cells were then detached, 
washed twice with PBS, and suspended in 100 μL of binding buffer (10 mM HEPES/ 
NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl2), after which they were stained and assessed 
by flow cytometey as described above. 
 
ROS generation analysis 
ROS levels were determined by staining cells with 2.5 μM 2′,7′-Dichlorofluorescin 
diacetate (DCFDA) (MERCK). In brief, 5x104 cells/well were incubated with ICRP CC50 
for 24 h in presence or absence of 1.5 mM BAPTA (MERCK). Cells were then detached, 
washed with PBS, stained, incubated at 37 °C for 30 min, and measured using a flow 
cytometer, as mention above. 
 
Mitochondrional membrane potential analysis 
Mitochondrional membrane potential was measured using 500 nM TMRE (MERCK). In 
brief, 5x104 cells in 24-well dishes were incubated with ICRP CC50 for 24 h in presence 
or absence of 1.5 mM BAPTA (MERCK). Cells were then harvested, washed with PBS, 
stained, incubated at 37°C for 30 min, and measured by flow cytometry as described 
above. 
 
Calreticulin exposure analysis 
For this, 5x104 cells were seeded in 24-well plates and treated with ICRP CC50 for 24 h in 
presence or absence of 1.5 mM BAPTA (MERCK). Cells were detached, washed, stained 
with Calreticulin-Phycoerythrin antibody (0.1 μL of a 1 to 1000 dilution) (Calreticulin-
PE, FMC-75; Enzo Life Science, Farmingdale, NY) in 2%-FACS buffer, and incubated 1 
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h in darkness at 25 ºC, after that, cells were washed and suspended in 100 μL of 2%-FACS 
buffer to be assessed by flow cytometry as described above. 
 
Autophagosome formation assay 
For this evaluation, 5x104 cells were cultured in 24-well plates (Life Sciences) with ICRP 
CC50 for 24 h. Cells were then detached, washed with PBS, stained with Autophagy 
Detection Kit (Abcam, Cambridge, UK), and measured by flow cytometry, as explained 
above. 
 
EIF2α phosphorylation assay 
For this assay, 5x105 cells were plated in 6-well dishes (Life Sciences) in complete 
DMEM to a final volume of 2 mL, and incubated with ICRP CC50 for 18 h. Cells were 
then collected and fixed with eBioscience Foxp3/transcription factor 
fixation/permeabilization concentrate and diluent (Life Technologies) for 1 h at 4 °C. 
Cells were then washed with 2%-FACS Buffer (PBS 1x and 2% FBS) and centrifuged 
twice at 1,800 rpm during 20 min. Next, cells were suspended in 50 μL of 10%-FACS 
Buffer (PBS 1x and 10 % FBS), incubated for 30 min, and shaken at 400 rpm and 25 °C. 
After this, 0.5 μL of anti-EIF2S1 (phospho S51) antibody [E90] (Abcam, ab32157) was 
added, incubated for 2 h, and washed with 2%-FACS Buffer.  Cells were suspended in 
100 μL of 10%-FACS Buffer), incubated for 15 min, and shaken at 400 rpm and 25 °C, 
0.5 μL of goat anti-rabbit IgG H&L (Alexa Fluor® 488) (Abcam, ab150077) was then 
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added and incubated for 1h in darkness. Cells were washed with 2%-FACS Buffer and 
eIF2α phosphorylation was measured by flow cytometry, as mention before. 
 
ATP release assay 
Supernatants of ICRP CC50-treated cells (2x105) were used to assess extracellular ATP by 
a luciferase assay (ENLITEN kit, Promega, Madison, WI), following manufacturer’s 
instructions. Bioluminescence was determined in a Synergy HT microplate reader, using 
the Software Gen5 (BioTek, Winooski, VT) at 560 nm. 
 
High-mobility group box 1 release assay 
For this assay, 2x105 were treated with ICRP CC50 for 24 h. Supernatants were used to 
assess extracellular HMGB1 using the HMGB1 BioAssay ELISA Kit (Human) for MCF-
7 and the HMGB1 BioAssay ELISA Kit (Mouse) for 4T1 cells (US Biological Life 
Science), following manufacturer’s instructions, in a spectrophotometer at a wavelength 
of 450 nm. 
 
Generation of mouse BMDCs 
To obtain bone marrow-derived dendritic cells (BMDCs), seven-to-eight-week-old 
BALB/c mice were anesthetized with an intraperitoneal injection of ketamine (80 mg/kg 
body weight) and xylazine (10 mg/kg body weight) and were euthanized by cervical 
dislocation (n= 5 mice). Bone marrow was removed from femur and tibia after mouse 
death by flushing into complete RPMI (Life Technologies). Eluted cells were cultured at 
37 ºC in a controlled humidified atmosphere with 5 % CO2 for 5 days in complete RPMI 
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and 20 ng/mL IL-4 and GM-CSF (R&D Systems, Minneapolis, MN), until approximately 
50 % of cells were CD11c+. 
 
T cells-isolation 
Seven-to-eight-week-old BALB/c mice were anesthetized as mentioned above. Blood was 
obtained by cardiac puncture, and then cervical dislocation was performed. Peripheral 
blood mononuclear cells (PBMCs) isolation was performed by density gradient 
centrifugation, using Ficoll-Hypaque-1119 (MERCK). CD3+ cells were isolated from 
total PBMCs by positive selection using magnetic-activated cell sorting microbead 
technology with anti-CD3𝜀-biotin and anti-biotin microbeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany), following manufacturer’s instructions. Primary murine CD3+ cells 
were maintained in complete RPMI and incubated at 37 ºC in a controlled humidified 
atmosphere with 5 % CO2. 
 
ICRP-TCL-mediated BMDCs maturation 
BMDCs were suspended in complete RPMI at a concentration of 1x106 cells/mL and 
stimulated with ICRP-tumor cell lysate (ICRP-TCL) (3x106 cells/mL at a ratio of 1:3 
BMDCs to ICRP-treated 4T1 cells (BMDCs-ICRP-TCL)). Control BMDCs were left 
untreated or stimulated with 1 μg/mL lipopolysaccharide (LPS) (MERCK). After 24 h, 
culture supernatants were removed and stored at -80 ºC to analyze TNF-α release by flow 
cytometry (BD CBA Mouse Th1/Th2 Cytokine Kit, BD Biosciences, San Jose, CA), and 
wells were washed twice with PBS before the next co-culture (with the addition of T 
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lymphocytes). Additionally, some BMDCs-Control and BMDCs-ICRP-TCL wells were 
collected to analyze DCs markers expression. 
 
DCs markers expression 
For this assay, 1x105 BMDCs were suspended in 100 μL of 2%-FACS buffer, and 
maturation was analyzed by immunostaining using anti-CD11c-Alexafluor 488 (R&D 
Systems, Minneapolis, MN), anti-CD80-FITC, and anti-CD86-APC (BD Biosciences) at 
25 °C for 30 min, and washed twice with PBS. Cell surface markers were evaluated by 
flow cytometry, as mention above. 
 
BMDCs-T-lymphocytes co-culture 
BMDCs-Control or BMDCs-ICRP-TCL were maintained in complete RPMI at a 
concentration of 1x106 cells/mL. Allogeneic BALB/c mCD3+ cells were then added to 
each well at 3x106 cells/mL (at a ratio of 1:3 DCs to CD3+ cells), and incubated for 96 h 
at 5 % CO2 and 37 °C. Supernatants were then removed, stored at -80 ºC to further analyze 
TNF-α and IFN-γ levels by flow cytometry (BD CBA Mouse Th1/Th2 Cytokine Kit, BD 
Biosciences), and lymphocytes were washed with PBS, and suspended in complete RPMI 
to be used in the next co-culture (T-lymphocytes with cancer cells). 
 
T-Lymphocytes-4T1 cells co-culture 
Viable 4T1 cells were seeded at a concentration of 1x105 cells/mL. Cells were then stained 
with 0.1 μL/mL of calcein-AM (BD Biosciences) for 30 min and washed twice with PBS. 
Next, unprimed (previously co-cultured with BMDCs-Control) or primed (previously co-
cultured with BMDCs-ICRP-TCL) allogeneic BALB/c CD3+ cells were added to each 
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well at 5x105 cells/mL (at a ratio of 1:5 cancer cells to CD3+ cells); 4T1-T-lymphocytes 
co-culture was incubated at 37 ºC and 5 % CO2 for 24 h. Supernatants were removed and 
stored at -80ºC to further analyze IFN-γ levels, as mentioned above. Cancer cells were 
then washed and detached to analyze 4T1-calcein negative cells by flow cytometry, as 
described above. 
 
Prophylactic vaccination with ICRP-TCL 
For this, 4T1 cells were treated with 0.5 U/mL ICRP for 24 h; cells were then washed, 
detached, and cell death was confirmed using trypan blue staining and flow cytometry, as 
previously indicated. Seven-to-eight-week-old BALB/c mice were inoculated 
subcutaneously (s.c.) with 1.5x106 dying 4T1 cells (n=10 mice) or with PBS (n=6 mice) 
on the left flank side. On day 7 after vaccination, the mice were challenged s.c. on the 
opposite flank with 5x105 living 4T1 cells. 
 
Therapeutic vaccination with ICRP-TCL 
For this evaluation, mice were inoculated s.c. with 5x105 live 4T1 cells on the right flank 
side. When tumors reached 100 mm3 (on day 3 after cancer cell inoculation), mice were 
treated s.c. with 1.5x106 dying 4T1 cells on the opposite flank during two weeks (two 
times per week) (n=9 mice); mice injected with PBS were used as control (n=5 mice). 
 
Tumor volume measurements 
Tumor volume was measured three times a week, using a caliper (Digimatic Caliper 
Mitutoyo Corporation, Japan), this was determined with the following formula: tumor 
volume (mm3) = 4𝜋 / 3 ∗ A (length) ∗ B (width) ∗ C (height). When tumors exceeded 
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1000 mm3 mice were anesthetized as described above and were euthanized by cervical 
dislocation. 
 
Long-term memory assays 
Mice in complete remission after ICRP-TCL prophylactic (n=9 mice) and therapeutic 
vaccinations (n=8 mice) were re-challenged with 5x105 living 4T1 cells in 100 μL of PBS 
into the opposite flank, and naïve mice were used as control (n= 5 mice). Tumor volume 
and mice survival was evaluated, as described above. 
 
Additionally, tissues from tumor-draining lymph nodes (TDLN) and tumor re-challenge 
sites were obtained from naïve mice and mice in complete remission after ICRP-TCL 
prophylactic vaccination, three days after tumor re-challenge. Tissues were fixed in 3.7% 
neutral formalin, embedded in paraffin, sectioned (5 μm thickness) and stained with H&E 
(MERCK). Histopathological analyses were done by an external veterinarian pathologist 
(National professional certificate 2593012). Blood was obtained by cardiac puncture from 
anesthetized mice as described above, and PBMCs isolation was performed by density 
gradient centrifugation, using Ficoll-Hypaque-1119 (MERCK). Cells from TDLN and 
spleen were isolated using 70 μm cell strainers (MERCK) and suspended in 2%-FACS 
buffer. PBMCs were stained with Mouse T lymphocyte antibody cocktail: PE-Cy7 CD3e, 
PE CD4, and FITC CD8 (BD Pharmingen) following manufacturer's instructions. 
Maturation of DCs was analyzed by immunostaining of cells from lymph nodes using 
anti-CD11c-Alexafluor 488 (R&D Systems), and anti-CD86-APC (BD Biosciences) at 25 
°C for 30 min and washed twice with PBS. Cell surface markers were evaluated by flow 
cytometry, as mention above. Viable 4T1 cells were seeded at a concentration of 1x105 
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cells/mL, stained with 0.1 μL/mL of calcein-AM (BD Biosciences) for 30 min and washed 
twice with PBS. Next, splenocytes from naïve or ICRP-TCL mice were added to each well 
at 40x105 cells/mL (at a ratio of 1:40 cancer cells to splenocytes); 4T1-splenocytes co-
culture was incubated at 37 ºC and 5 % CO2 for 24 h. Supernatants were removed and 
stored at -80 ºC to further analyze IFN-γ levels, as mentioned above. Cancer cells were 
then washed and detached to analyze 4T1-calcein negative cells by flow cytometry, as 
described above (n=6 mice per group). 
 
Statistical Analysis 
Data were analyzed using GraphPad Prism Software (GraphPad Software Inc., San Diego, 
CA) and showed as mean ± SD of triplicates from three independent experiments. For in 
vitro studies, statistical analysis was done using paired Student’s t-test, and for in vivo and 






1. IMMUNEPOTENT CRP induces regulated cell death in a concentration-
dependent manner on breast cancer cells. 
To archive the objectives of the project, the first step was to determinate the cytotoxic 
concentration of ICRP that induced 50% of cell death (CC50) in MCF-7 and 4T1 cells, that 
were then used for next evaluations. ICRP induced regulated cell death in all cell lines 
after 24 h of treatment in a concentration-dependent manner, as shown in Figure 14. Cell 
death in 30% of the cells (CC30) was reached at 1 U/mL in MCF-7, and 0.1 U/mL in 4T1 
cells. CC50 by ICRP was caused at 1.25 U/mL in MCF-7, and 0.15 U/mL in 4T1 cells, 
whereas CC80 was induced at 1.5 U/mL in MCF-7, and 0.2 U/mL in 4T1 cells, and CC90 
was reached at 2 U/mL in MCF-7 and 0.5 U/mL in 4T1 cells (Fig. 14). 
 
 
Figure 14. IMMUNEPOTENT CRP induces regulated cell death in a concentration-dependent 
manner in breast cancer cells. A-B. Representative dot plots (left) and quantifications (right) of cell death 
measured by flow cytometry through Annexin-V and PI staining in MCF-7 (A) and 4T1 cells (B) treated 
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with different concentrations of ICRP for 24 h. The means (± SD) of triplicates of at least three independent 
experiments were graphed. 
 
2. IMMUNEPOTENT CRP increases cytoplasmic Ca2+ levels in breast cancer cells. 
With the purpose of describing the implication of Ca2+ in the mechanism of cell death 
induced by ICRP, cytosolic Ca2+ levels in MCF-7 and 4T1 cells were first assessed by 
confocal microscopy. Results indicated that 18 h-treatment with CC50 of ICRP induced an 
augmentation of Ca2+ levels in the cytoplasm in comparison with untreated cells (control) 
(Fig. 15A and 15B). Thus, cytosolic level of Ca2+ was quantified by flow cytometry, data 
showed that ICRP CC50 treatment for 18 h induced an increment in Ca2+ concentration in 
the cytoplasm in 40% to 50% of breast cancer cells (Fig. 15C and 15D). 
 
Figure 15. IMMUNEPOTENT CRP induces an increase in the cytoplasmic Ca2+ levels of MCF-7 and 
4T1 cells. A-B. Confocal microscopy representation of Ca2+ cytoplasmic levels measured through Fluo-4 
AM staining in MCF-7 (A) and 4T1 cells (B) in absence (control) or presence of ICRP CC50 for 18 h. C-D. 
Representative histograms (left) and quantifications (right) of Ca2+ cytoplasmic levels assessed through 
Fluo-4 AM staining by flow cytometry in absence (control) or presence of ICRP CC50 for 18 h in MCF-7 
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(C) and 4T1 (D) cells. Graphs represent the means (± SD) of triplicates of at least three independent 
experiments. 
 
3. IMMUNEPOTENT CRP triggers Ca2+-dependent ROS production, loss of Δψm, 
and CRT exposure, which led to cell death in breast cancer cells. 
As an increase of cytosolic Ca2+ levels was observed in breast cancer cells after ICRP 
treatment, the implication of Ca2+ augmentation in cell death was analyzed by assessing 
ICRP-induced cell death in presence or absence of the extracellular Ca2+ chelator BAPTA. 
As observed in Figure 16, ICRP induced regulated cell death in up to 50% of cells after 
24-h treatment, and this cytotoxicity was significantly inhibited in presence of BAPTA, 













Figure 16. IMMUNEPOTENT CRP induces Ca2+-dependent cell death in breast cancer cells. A-B. 
Representative dot plots (left) and quantifications (right) of cell death measured by flow cytometry through 
Annexin-V and PI staining in MCF-7 (A) and 4T1 cells (B) treated with ICRP CC50 for 24 h in presence or 
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absence of BAPTA. Graphs represent the means (± SD) of triplicates of at least three independent 
experiments. 
 
Then, Dym and ROS production were evaluated in presence or absence of BAPTA, as 
these processes have been observed in ICRP-induced cell death in cancer cells, and they 
are associated with Ca2+ deregulation. As observed in Figure 17, ICRP caused loss of Dym 
in up to 60% of cells, and this cellular process was significantly inhibited in presence of 
BAPTA. In addition, ICRP triggered ROS production in up to 55% of cells, which was 
also inhibited in presence of BAPTA (Fig. 18). Thus, ICRP generated a Ca2+-dependent 














Figure 17. The loss of mitochondrial membrane potential mediated by IMMUNEPOTENT CRP 
requires Ca2+ influx from extracellular space in breast cancer cells. A-B.  Representative histograms 
(left) and quantifications (right) of loss of mitochondrial membrane potential evaluated through TMRE 
staining by flow cytometry in MCF-7 (A) and 4T1 cells (B) treated with ICRP CC50 for 24 h in presence or 
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Figure 18. IMMUNEPOTENT CRP triggers Ca2+-dependent ROS production in breast cancer cells. 
A-B. Representative histograms (left) and quantifications (right) of ROS production assessed through 
DCFDA staining by flow cytometry in MCF-7 (A) and 4T1 cells (B) treated with ICRP CC50 for 24 h in 
presence or absence of BAPTA. Graphs represent the means (± SD) of triplicates of at least three 
independent experiments. 
 
Furthermore, CRT exposure was evaluated after ICRP treatment in presence or absence 
of BAPTA, as exposure of this protein is associated with ER stress, which is the major 
storage of Ca2+ within the cell. As observed in Figure 19, CRT exposure was observed 
after ICRP CC50 treatment for 24 h in up to 60% of cells, which was significantly inhibited 

















Figure 19. IMMUNEPOTENT CRP triggers Ca2+-dependent CRT exposure in MCF-7 and 4T1 cells. 
A-B. Representative histograms (left) and quantifications (right) of CRT exposure assessed through 
Calreticulin-PE antibody staining by flow cytometry in MCF-7 (A) and 4T1 cells (B) treated with ICRP 
CC50 for 24 h in presence or absence of BAPTA. Graphs represent the means (± SD) of triplicates of at least 
three independent experiments. 
 
4. IMMUNEPOTENT CRP causes ER stress, autophagosome formation and 
DAMPs release in breast cancer cells. 
P-eIF2α regularly antecedes CRT exposure in the course of ICD, nonetheless P-eIF2α is 
not necessarily followed by CRT exposure, particularly when the ER stress response 
reestablishes cell homeostasis, and thus, P-eIF2α was evaluated after ICRP treatment. 
ICRP induced P-eIF2α in 50% to 60% of breast cancer cells treated with ICRP CC50 for 
18 h (Fig. 20A). In addition, autophagosome formation was induced by 24-h treatment 
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with ICRP CC50 in 40% to 55% of MCF-7 and 4T1 cells (Fig. 20B). CRT exposure, ER 
stress, and autophagosome formation are part of the principal biochemical processes of 
ICD. Thus, the release of ATP and HMGB1 (DAMPs associated with ICD) were assessed 
after ICRP exposure. As observed in Figure 20C and 20D, ICRP induced 276- and 11-
fold ATP release, and 1.6-, and 1.3-fold HMBG1 release in MCF-7 and 4T1 cells, 
respectively, as compared with untreated control. 
Figure 20. 
IMMUNEPOTENT CRP triggers ER stress, autophagosome formation, and DAMPs release in MCF-
7 and 4T1 cells. A. Representative FACS histograms of P-eIF2α staining (in grey) and IgG isotype 
antibodies (dotted) of cancer cells left untreated (control) or treated with ICRP CC50 for 24 h. Charts are the 
quantification of P-eIF2α staining in controls and cancer cells treated with ICRP. B. Representative 
histograms (left) and quantifications (right) of autophagosome formation measured through Green Detection 
Reagent staining by flow cytometry in absence (control) or presence of ICRP CC50 for 24 h in MCF-7 and 
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4T1 cells. C-D. Quantification of ATP release through bioluminescence detection (C) and HMGB1 release 
assessed by ELISA (D) in supernatants of MCF-7 and 4T1 cells in absence or presence of ICRP CC50 for 
24 h. Graphs represent the means (± SD) of triplicates of at least three independent experiments. 
 
5. ICRP- treated tumor cell lysate induces maturation of BMDCs. 
After determining that the principal biochemical characteristics of immunogenic cell death 
were evoked by ICRP, we evaluated the capacity of ICRP-TCL to maturate BMDCs. As 
observed in Figure 21A and 21B, the exposure of BMDCs to ICRP-TCL (BMDCs-ICRP-
TCL) significantly increased the expression of CD80 (57%), and CD86 (65%); whereas 
maintaining CD11c expression (48%), in comparison with unstimulated BMDCs (C80: 
44%, CD86: 45%, and CD11c: 49%). These results resemble the ones observed by our 
positive control, LPS, which significantly incremented CD80 (56%) and CD86 expression 
(70%); and also maintained CD11c expression (48%) in these cells.  
 
Furthermore, a significant increase of TNF-α release was observed in BMDCs stimulated 
with ICRP-TCL (760 pg/mL) or LPS (7763 pg/mL), in comparison with unstimulated 







Figure 21. ICRP-TCL induces BMDCs maturation. A. Representative flow cytometry histograms 
showing the percentage of CD80+, CD86+, and CD11c+ BMDCs unstimulated (negative control), in co-
culture ratio 1:3 with ICRP-treated 4T1 cells (ICRP-TCL), or stimulated with 1 μg/mL of LPS (positive 
control) during 24 h. B.  BMDCs were treated as in A and the means (± SD) obtained of five independent 
experiments were graphed. C. Quantification of TNF-α concentration in supernatants of BMDCs treated as 
in A, expressed as the means (± SD) of five independent experiments. n= 5 mice per group. 
 
6. Mature BMDCs exposed to ICRP-tumor cell lysate triggers anticancer immune 
responses. 
After the evaluation of ICRP-TCL-mediated BMDCs maturation, the next step was to 
investigate if these mature cells could induce T cell priming. Figure 22A and 22B show a 
significant increase of TNF-α (380 pg/mL) and IFN-γ (650 pg/mL) release in co-culture 
of BMDCs-ICRP-TCL and T cells, in contrast BMDCs-Control and T cells co-culture 





















Figure 22. BMDCs exposed to ICRP-TCL triggers anticancer immune response. A-B. Concentration 
of TNF-α (A) and IFN-γ (B) in supernatants of unstimulated BMDCs (BMDCs-Control) or stimulated with 
ICRP-TCL (BMDCs-ICRP-TCL), in co-culture ratio 1:3 with T cells for 96 h, expressed as the means (± 
SD) of five independent experiments. C. Representative flow cytometry histograms showing the percentage 
of calcein negative 4T1 cells left alone (Control), or in co-culture ratio 1:5 with unprimed T-lymphocytes 
(previously co-cultured with unstimulated BMDCs) or primed T-lymphocytes (previously co-cultured with 
BMDCs-ICRP-TCL) for 24 h. D. Percentage of calcein negative 4T1 cells treated as in C. E. Quantification 
of IFN-γ concentration in supernatants of 4T1 cells treated as in C, expressed as the means (± SD) of three 
independent experiments. n= 5 mice per group. 
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Primed T cells obtained after co-culture with BMDCs-ICRP-TCL caused a cytotoxic 
effect in up to 70% of 4T1 cells, whereas the cytotoxicity induced by unprimed T cells 
was up to 19% of cancer cells; no cytotoxicity was detected in 4T1 cells without T cells 
(Fig. 22C and Fig. 22D). In addition, a significant increase of IFN-γ release was observed 
in the co-culture of primed T cells with 4T1 cancer cells (192 pg/mL), in comparison with 
the co-culture of unprimed t cells with 4T1 cells (8 pg/mL) (Fig. 22E). These data confirm 
the efficient antigen presentation by BMDCs-ICRP-TCL to T cells and the 
immunocompetence of these T cells against 4T1 cells. 
 
7. Prophylactic vaccination with ICRP-TCL prevents tumor establishment in 
BALB/c mice. 
In order to test the ability of ICRP-TCL to activate adaptive immune system in vivo, we 
performed a well-established prophylactic tumor vaccination model in immunocompetent 
BALB/c mice (Fig. 23A). Immunization of mice with ICRP-TCL prevented tumor growth 
at the challenge site in nine out of ten mice, moreover, the tumors growing on the 
challenge site of the unvaccinated (PBS) mice reached up to 1 200 mm3 in all six mice 
(Fig. 23B), confirming that ICRP-TCL induced a potent immune response in vivo, 
reflected in 90% (9/10) of 60-day survival rates of mice in ICRP-TCL group, whereas all 
control mice were euthanized by day 20 (6/6) (Fig. 23C). 
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8. Prophylactic vaccination with ICRP-TCL induces long-term antitumor memory 
in BALB/c mice. 
To investigate the effect of ICRP-TCL on the memory response in vivo, tumor-free mice 
that survived 150 days from a previous prophylactic vaccination with ICRP-TCL were re-
challenged with living 4T1 cancer cells, naïve mice challenged with living 4T1 cancer 
cells were used as control (Fig. 24A). Results show that tumor growth was prevented in 
re-challenged mice, while continuous tumor growth was observed in naïve mice, 
challenged for the first time (Fig. 24B). This reflected in 100% (9/9) of survival in ICRP-
TCL re-challenged mice, while naïve mice perished by day 15 (5/5) (Fig. 24C). These 
results strongly suggest the stimulation of long-term antitumor immune memory by ICRP-
TCL prophylactic vaccination.  
 
To better characterize this immune response we assessed tumor establishment, DCs 
maturation, T cell distribution, and splenocytes-tumor specific cytotoxicity after three 
days of tumor challenge (naïve mice) / re-challenge (ICRP-TCL) (Fig. 25A).  
 
Results reveal that naïve mice presented tumor establishment with an extensive infiltration 
of neoplastic cells in the striated muscle tissue; furthermore, these cells demonstrated an 
intense mitotic activity (Fig. 25B left). On the other hand, ICRP-TCL mice showed a 
discrete infiltration of neoplastic cells in the striated muscle tissue, observing a strong 
infiltration of lymphocytes and polymorphonuclear cells (Fig. 25B right).  
 
Moreover, histopathological analyses from tumor-draining lymph nodes showed a diffuse 
lymphoid hyperplasia in naïve mice, whereas ICRP-TCL mice present a follicular 
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lymphoid hyperplasia, indicating a modulated response associated with immunological 
memory (Fig. 25C).  
 
Due to these differences, we next evaluated the proportion of mature dendritic cells in 
tumor draining lymph nodes. Results indicated that re-challenged ICRP-TCL group did 
not show significant difference in the percentage of DCs, but a higher proportion of mature 
DCs (CD11c+CD86+) were present when compared with challenged naïve mice (Fig. 
25D).  
 
Then, we assessed the proportion of T cells in peripheral blood, and no differences were 
detected in total CD3+ cells, while a significant decrease of CD4+ T cells and an increase 
of CD8+ T cells was observed in ICRP-TCL mice, when compared with naïve mice (Fig. 
25E).  
 
Furthermore, splenocytes from ICRP-TCL mice mediated a cytotoxic effect in 4T1 cells, 
inducing loss of cell viability in up to 50% of cancer cells, whereas no significant cytotoxic 
effect was detected in 4T1 cells co-cultured with splenocytes from naïve mice (Fig. 25F). 
Finally, a significant increase of IFN-γ release was observed in the co-culture of 4T1 cells 
with splenocytes from ICRP-TCL mice (95 pg/mL), in comparison with the co-culture of 







Figure 23. Prophylactic vaccination with ICRP-TCL prevented tumor establishment in BALB/c mice. 
A. Mice were inoculated s.c. with 1.5x106 dying 4T1 cells or with PBS on the left flank side. On day 7 after 
vaccination, mice were challenged s.c. on the opposite flank with 5x105 living 4T1 cells. Tumor growth on 
the challenge site was evaluated for up to 60 days after the challenge. B. Tumor volume on the challenge 
site of unvaccinated mice (Control, n= 6 mice) or vaccinated with 1.5x106 ICRP-treated 4T1 cells (ICRP-
TCL, n= 10 mice). Each line represents one mouse. C. Kaplan Meier graph with the percentage of survival 










Figure 24. Prophylactic vaccination with ICRP-TCL induces long-term antitumor memory in 
BALB/c mice. A. Mice in remission after ICRP-TCL prophylactic vaccination were re-challenged s.c. with 
5x105 living 4T1 cells after 150 days of prophylactic vaccination. Tumor growth on the challenge site was 
evaluated for up to 60 days after re-challenge. B. Tumor volume on the challenge site of naïve mice (black 
square, n= 5 mice) or mice in remission after a previous 1.5x106 ICRP-TCL vaccination (white circle, n= 9 




Figure 25. ICRP-TCL prophylactic vaccination modulates tumor establishment, DCs maturation, T 
cell distribution, and splenocytes-tumor specific cytotoxicity after tumor re-challenge. A. Naïve mice 
(n=6) and mice in remission after ICRP-TCL prophylactic vaccination (n=6) were challenged / re-
challenged s.c. with 5x105 living 4T1 cells. Three days later, the tumor re-challenge site, tumor-draining 
lymph nodes, peripheral blood, and spleen were obtained. B-C. Histology from tumor re-challenge sites (B) 
and lymph nodes (C) of naïve and ICRP-TCL mice stained with H&E. Normal tissue (white arrows), tumor 
cells (red arrows), mitotic cells (black arrows), lymphocytes (blue arrows), polymorphonuclear cells (green 
arrows). D. Percentage of CD11c and CD86 positive cells in tumor draining lymph nodes of naïve and 
ICRP-TCL mice E. Proportion of CD3, CD4, and CD8 positive cells in peripheral blood of naïve and ICRP-
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TCL mice. F. Percentage of calcein negative 4T1 cells left alone (Control), or co-cultured with splenocytes 
from naïve or ICRP-TCL mice for 24 h (co-culture ratio 1:40). G. Quantification of IFN-γ concentration in 
supernatants of co-cultures obtained as in F, expressed as the means (± SD) of three independent 
experiments (n= 6 mice per group). 
 
9. Therapeutic vaccinations with ICRP-TCL induce tumor regression in tumor-
bearing mice, and long-term antitumor memory. 
After the evaluation of the immunogenicity of ICRP-induced cell death, the therapeutic 
potential of ICRP-TCL per se was tested in tumor-bearing mice. For this, BALB/c mice 
were inoculated with 5x105 living 4T1 cells, and when tumors reached 100 mm3, 
therapeutic vaccinations were performed every three days during two weeks with s.c. 
inoculation of 1.5x106 dying 4T1 cells (ICRP-TCL) or PBS (control) on the opposite flank 
(Fig. 26A).  
 
Therapeutic vaccinations with ICRP-TCL induced tumor regression in eight out of nine 
mice, whereas, the tumors growing on control group reached up to 600 mm3 in all five 
mice (Fig 26B), reflected in 88.88% (8/9) of 60-day survival rates of mice in ICRP-TCL 
group, whereas all control mice were euthanized by day 19 (5/5) (Fig. 26C). Tumor-free 
mice that survived 150 days from previous therapeutic vaccinations with ICRP-TCL were 
then re-challenged with living 4T1 cancer cells. Naïve mice challenged with living 4T1 
cancer cells were used as control (Fig. 27A). Results demonstrated that tumor growth was 
prevented in re-challenged mice, while continuous tumor growth was observed in naïve 
mice, challenged for the first time (Fig. 27B). This was reflected in 100% (8/8) of survival 
in ICRP-TCL re-challenged mice, while naïve mice were euthanized by day 15 (5/5) (Fig. 
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27C). These results strongly suggest the stimulation of long-term antitumor immune 
memory by ICRP-TCL therapeutic vaccinations. 
 
 
Figure 26. Therapeutic vaccinations with ICRP-TCL induce tumor regression in tumor-bearing 
BALB/c mice. A. Mice were inoculated s.c. with 5x105 living 4T1 cells on the left flank side. When tumors 
reached 100 mm3, therapeutic vaccinations were performed every three days during two weeks with s.c. 
inoculation of 1.5x106 dying 4T1 cells (ICRP-TCL) on the opposite flank. PBS injections served as control. 
Tumor growth on the challenge site was evaluated for up to 60 days after the challenge. B. Tumor volume 
on the challenge site of control mice (n= 5 mice) or mice treated with 1.5x106 ICRP-treated 4T1 cells (ICRP-
TCL, n= 9 mice). Each line represents one mouse. C. Kaplan Meier graph with the percentage of survival 









Figure 27. Therapeutic vaccinations with ICRP-TCL induce long-term antitumor memory in BALB/c 
mice. A. Mice in remission after ICRP-TCL therapeutic vaccinations were re-challenged s.c. with 5x105 
living 4T1 cells after 150 days of the first inoculation. Tumor growth on the challenge site was evaluated 
for up to 60 days after re-challenge. B. Tumor volume on the challenge site of naïve mice (black square, n= 
5 mice) or mice in remission after a previous 1.5x106 ICRP-TCL vaccinations (white circle, n= 8 mice). C. 




The results obtained in this work demonstrated the Ca2+-dependence in ICRP-induced cell 
death in MCF-7 and 4T1 cells and indicate that IMMUNEPOTENT CRP may have the 
capacity to turn breast cancer cells into potential vaccines in vivo, through immunogenic 
cell death induction.  
 
In this section I considered important to discuss the following core aspects of the cytotoxic 
mechanism of IMMUNEPOTENT CRP in cancer cells, and its application on cancer-
therapy: 
 
• The role of Ca2+ in the duality of IMMUNEPOTENT CRP 
• Biochemical characteristics of IMMUNEPOTENT CRP-mediated cell death in 
cancer 
• ICRP-mediated cell death can return cancer cells to their immunity-cycle 
• IMMUNEPOTENT CRP is a bona fide immunogenic cell death inducer 
• Therapeutic potential of tumor cell lysates obtained by ICRP treatment 
• IMMUNEPOTENT CRP in the landscape of cancer therapy 
 
The role of Ca2+ in the duality of IMMUNEPOTENT CRP 
 
IMMUNEPOTENT CRP is a promising immunotherapy with antitumoral and 
immunomodulatory effects. Cancer cells exposed to ICRP treatment succumb to regulated 
cell death (Martinez-Torres et al. 2019; Martínez-Torres et al. 2018; Rodríguez-Salazar et 
 74	
al. 2017), nevertheless non-malignant cells, such as PBMCs and monocytes, did not exert 
cell death when are treated with ICRP (Franco-Molina et al. 2006; Sierra-Rivera et al. 
2016), hence ICRP induce a selective cytotoxicity on malignant cells.  
 
Here, it was proved that ICRP induced cell death in breast cancer cells via Ca2+ overload, 
this work demonstrated that the disruption of Ca2+ signaling mediated by ICRP is the first 
event described so far in the cytotoxic pathway of ICRP in cancer cells. It is important to 
mention that profound changes in the expression of Ca2+ channels and pumps can occur 
in some cancers, for instance, ORAI1 and TRPV6 expression is increased in the basal 
subtype of breast cancer, whereas ER+ breast cancer cells overexpress ORAI3 (Monteith, 
Prevarskaya, and Roberts-Thomson 2017). ORAI3 is capable of inducing a store-operated 
conductance, but its magnitude is considerably smaller than that seen with ORAI1 
(Shuttleworth 2012), this could be one of the main reasons of the sensibility for ICRP-
induced cell death observed in 4T1 cells in comparison with MCF7 cells. 
 
Alterations at the ER-mitochondria interface in breast cancer have also been reported, for 
instance, the expression of Sig1R is higher in metastatic potential breast cancer cells than 
in normal tissues, Sig1R binds to IP3R, thereby stabilizing IP3R at the MAMs and 
enhancing IP3R-mediated Ca2+ fluxes to the mitochondria. Also, high expression of IP3R3 
has been observed in human malignant tissues, this is important because compared with 
IP3R isoforms 1 and 2, which are located at the ER membranes, IP3R3 is highly enriched 
at the MAMs (and is considered a MAM marker) (Kerkhofs et al. 2017; Morciano et al. 
2018). This phenotype in cancer cells allows them to proliferate, as key cell cycle events 
rely on Ca2+ signaling, also, specific oncogene and pro-oncogene pathways involve Ca2+ 
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signaling, including those bestowing resistance to apoptosis. In addition, tumor cell 
migration and invasion are modulated by specific Ca2+-permeable ion channels, and 
signaling leading to epithelial to mesenchymal transition (EMT) phenotype is Ca2+-
dependent (Monteith, Prevarskaya, and Roberts-Thomson 2017). Hence, there is an 
opportunity to target the Ca2+ signaling in cancer, as these cells are more sensitive to the 
disruption of Ca2+ signaling, and this may promote or induce cancer cell death.  
 
It is not irrational to think that the selectivity of ICRP-induced cell death to cancer cells is 
because of differences between Ca2+ signaling in malignant and non-malignant cells. This 
has been already studied with other treatments, for instance, a CD47-agonist peptide 
triggered a transient increase of intracellular Ca2+ levels that then returned to baseline 
without inducing cell death in normal B cells, but in chronic lymphocytic leukemia cells, 
the treatment induced a strong and sustained Ca2+ mobilization that did not return to basal 
levels, leading to cell death (Martinez-Torres et al. 2015). Hence, it is important to 
evaluate the differences between Ca2+ signaling triggered by ICRP in normal and cancer 
cells.  
 
It is also interesting that ICRP treatments increased the expression of the activation marker 
CD69 in PBMCs. Whereas in NK cells, ICRP induced the activation of these cells and 
increased the degranulation marker CD107a (Manuscript in preparation). The activation 
of immune cells and the degranulation process in NK cells are two processes that have 
been widely associated with Ca2+ mobilization (Maul-Pavicic et al. 2011; Vig and Kinet 
2009). These findings suggest that ICRP may be able to trigger different Ca2+ signaling, 
one leading to the activation of immune cells and another one leading to the death of 
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cancer cells. However, Ca2+ signaling has not been demonstrated in immune cells treated 
with ICRP, thus, this opens a perspective of Ca2+ analysis on these cells. 
 
Biochemical characteristics of IMMUNEPOTENT CRP-mediated cell death in 
cancer 
 
ICRP induces a caspase-independent ROS-dependent regulated cell death in cervical and 
lung cancer cell lines, involving loss of Dym, cell cycle arrest and DNA degradation 
(Martinez-Torres et al. 2019; Martínez-Torres et al. 2018). Moreover, in leukemic cell 
lines ICRP induced apoptosis through ROS production, mitochondrial damage and 
nuclear alterations (Lorenzo-Anota et al. 2020), hence, ICRP triggers different cell death 
modalities depending on cancer cell lineage. In this work, it was demonstrated that ICRP 
induces regulated cell death, ROS production and Dym loss in breast cancer cells, thus, 
the conserved mechanisms of action between all cancer cell lines evaluated to this day 
include the overgeneration of ROS and loss of Dym.  
 
ROS production and loss of Dym are associated with deregulations in Ca2+ homeostasis 
(Orrenius, Zhivotovsky, and Nicotera 2003), furthermore, it has been demonstrated that 
ICRP induces calpain (Ca2+-dependent proteases) activation in HeLa cells (Robles-Reyes 
2011). Nevertheless, the implication of Ca2+ in ICRP-mediated cell death was unknown. 
Here, it was shown that ICRP induces cytoplasmic Ca2+ augmentation and ER stress, 
suggesting ER Ca2+ release. Additionally, it was demonstrated that the overgeneration of 
ROS, loss of Dym, and cell death mediated by ICRP in breast cancer cells require the 
influx of extracellular Ca2+. These results are similar to the cell death pathways described 
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in other treatments. In pancreatic tumor cells menadione induced ER-Ca2+ release, which 
was accompanied by mitochondrial Ca2+ elevation, mitochondrial depolarization, and 
mitochondrial permeability transition pore (mPTP) opening, leading to cell death 
(Baumgartner et al. 2009). Ceramide-induced cell death in HeLa cells involves ER-Ca2+ 
release and mitochondrial Ca2+ increase, accompanied by marked alterations in 
mitochondria morphology (Pinton et al. 2001). Also, cisplatin increased cytoplasmic and 
mitochondrial Ca2+ levels in HeLa cells, which further triggered mitochondrial-mediated 
and ER stress-associated cell death pathways, moreover, the inhibition of IP3Rs decreased 
calcium release from the ER and inhibited cisplatin-induced cell death (Shen et al. 2016).  
 
There are different pathways that can lead to the biochemical characteristics observed after 
ICRP treatment, for instance ICRP may induce Ca2+ depletion in ER, triggering ER stress 
that lead to CRT exposure and autophagosome formation as a consequence (Kepp et al. 
2015; Panaretakis et al. 2009). Moreover, Ca2+ released by ER could be transferred to 
mitochondrion through MAMs, generating Ca2+ overload, resulting in loss of Dym and 
ROS production (Kerkhofs et al. 2018). Ca2+ depletion from ER is well known to activate 
SOCE allowing the maintenance of high concentrations of Ca2+ inside the cell, which can 
lead to alterations in plasma membrane such as PS exposure and DNA degradation 
(Orrenius, Zhivotovsky, and Nicotera 2003), two processes that have been observed in 
ICRP-generated cell death (Martinez-Torres et al. 2019; Martínez-Torres et al. 2018; 
Lorenzo-Anota et al. 2020). However, there are missing pieces in the puzzle of ICRP-
mediated cell death, it is still unknown if ICRP generates Ca2+ depletion in ER-Ca2+ pool, 
and if so, how does ICRP generates it? As I mentioned before, this depletion could be 
modulated through IP3 generation by PLC or by calcium-induced calcium release process, 
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thus, it would be important to elucidate how is the initial pulse of Ca2+ induced, in the 
pathway triggered after ICRP treatment.  
 
In this work it was also demonstrated that CRT exposure triggered by ICRP treatment was 
inhibited when extracellular Ca2+ was chelated, this indicates that the Ca2+ influx from the 
extracellular space is required for an ER stress induction. These data suggest that the first 
pulse of Ca2+ might come from the extracellular space, stimulating calcium-induced 
calcium release process in ER, leading to Ca2+ depletion in ER, ER stress, and subsequent 
CRT exposure. However, this hypothesis must be verified with more studies. Dependence 
of Ca2+ fluxes for CRT exposure has been observed with other treatments, for instance, 
mitoxanthrone induced ER Ca2+ depletion that favors the exposure of CRT (Tufi et al. 
2008).  
 
According to these data, I hold the belief that the molecules that are present in the ICRP 
(such as cyclic nucleotides) might stimulate second messenger-operated channels 
(SMOCs), or ICRP might cause alterations in the membrane potential meaning a 
depolarization (which activates voltage-operated channels-VOCs) or hyperpolarization 
(which activates the transient receptor potential (TRP) ion-channel family), any of these 
events will allow the entry of Ca2+ into the cells, then, the calcium-induced calcium release 
process (CICR), whereby Ca2+ promotes its own release from ER, might amplifies these 
microscopic initiation pulses into Ca2+ propagating signals. CICR could cause depletion 
of Ca2+ from ER, leading to CRT exposure and the opening of store-operated channel 
(SOC), a plasma-membrane ion channel, that opens in response to the depletion of internal 
Ca2+ stores, which will increase dramatically the levels of Ca2+ in the cells leading to DNA 
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degradation after the activation of Ca2+-dependent enzymes and also the activation of 
proteases. In addition, Ca2+ could be transported across the OMM and IMM of the 
mitochondrion, leading to a mitochondrial Ca2+overload, ROS production, and loss of 
mitochondrial membrane potential. In conjunction, all these processes will trigger 
regulated cell death in cancer cells. However, it would be a rash to propose a detailed 
mechanism of action at this point, and further analysis and information is required.   
 
The results presented in this project demonstrated that ICRP treatment increased 
autophagosome formation in breast cancer cells, it has been observed that autophagy plays 
different roles in the immunogenicity of cell death. In 2011, Michaud and colleagues 
showed that autophagy is dispensable for chemotherapy-induced cell death but required 
for its immunogenicity, as autophagy-deficient cancer cells fail to attract DCs and T cells 
into the tumor bed after treatment with chemotherapy, this was supported with the 
observation of a decrease in DAMPs release from dying tumor cells when autophagy was 
inhibited (Michaud et al. 2011). Moreover, inhibition of autophagy diminishes HMGB1 
release (Tang et al. 2010; Thorburn et al. 2009). However, in 2013, Garg and colleagues 
showed that in contrast to expectations, ATG5 knockdown in cancer cells did not alter 
ATP secretion after Hyp-PDT. Furthermore, in response to Hyp-PDT, autophagy-
attenuated cancer cells displayed enhanced CRT exposure, increasing their ability to 
induce DCs maturation and T cell proliferation (Garg et al. 2013). Hence, although it has 
been demonstrated that ICRP induces pro-survival autophagosome formation (Alvarez-
Valdez, 2018), the role of autophagy in the immunogenicity of ICRP-induced cell death 
should be better described in further analysis. 
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In spite of the fact that the exact role of autophagy in ICRP-induced cell death 
immunogenicity has not been demonstrated, here it was shown that ICRP could trigger 
significative ATP secretion in MCF-7 and 4T1 cells, corresponding with the previous 
observation that autophagic vesicles loaded with ATP can fusion with the plasma 
membrane to release this nucleotide into the extracellular medium upon autophagy 
stimulation in a V-SNARE-dependent manner (Fader, Aguilera, and Colombo 2012). 
Additionally, higher levels of ATP release were observed in MCF-7 in comparison with 
4T1 cells. 4T1 is a p53 deficient cell line (Sang et al. 2005), and previous studies 
demonstrated that ATP is produced at higher levels using oxidative phosphorylation in 
HCT116 cells expressing p53 versus similar cells lacking p53 (Puzio-Kuter 2011). 
Furthermore, ICRP treatment triggered HMGB1 release in MCF-7 but partial HMGB1 
release in 4T1 cells. This low ICRP-mediated HMGB1 release could be due to the 
exposure of cells to ICRP CC50 treatment, which was not sufficient for a significant release 
of HMGB1, as some agents induce the release of HMGB1 at CC100 but not CC50 (Uscanga-
Palomeque et al. 2019). Also, it has been demonstrated that the release/exposure of all 
DAMPs is not determinant for immunogenic cell death (Garg et al. 2013), thus the 
immunogenicity of the cell death induced by ICRP was further evaluated ex vivo and in 
vivo. 
 
ICRP-mediated cell death can return cancer cells to their immunity-cycle 
 
Cancer-Immunity Cycle concept implies that tumor-associated antigens, accompanied by 
danger signals, are released by cancer cells and then captured by dendritic cells (DCs) for 
processing, promoting priming and activation of effector T cell responses against the 
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cancer-specific antigens, however, cancer cells develop strategies to escape from this 
cycle, and it has been proposed that an alternative to make cancer cells immunogenic, and 
return them to the cancer-immunity cycle is through the induction of ICD (Chen and 
Mellman 2013).  
 
Cancer dying cells by ICD inducers promote DCs maturation, which strongly activate 
anticancer immunity. According to current models, only few treatments induce 
intracellular signaling pathways that lead to a cancer cell death able to stimulate fully 
mature DCs, including γ-irradiation (Kim, Yun, and Han 2013), doxorubicin, oxaliplatin 
(Ghiringhelli et al. 2009), bortezomib (Cirone et al. 2012), and a CD47 agonist peptide 
(Martínez-Torres et al. 2019). Other therapies are only speculated to induce complete DCs 
maturation, or use LPS, IFN type 1, or others stimulants in combination with TCL to 
promote DCs’ maturation (Chen et al. 2012; Schiavoni et al. 2011). In addition, some 
cancer treatments may cause semi-mature DCs, namely DCs that lack of phenotypic 
maturation markers or cytokine release, and thereby are unable to efficiently prime T cells 
(Dudek, Martin, et al. 2013). Here, it was demonstrated that the tumor cell lysate (TCL) 
obtained from ICRP-treated 4T1 cells (ICRP-TCL) induced phenotypic and functional 
maturation of BMDCs. 
 
It has been observed that in the course of ICD, DAMPs exposure/release elicits the 
production of pro-inflammatory cytokines, such as TNF-α from DCs (Garg et al. 2016), 
here, ICRP-TCL triggered TNF-α release from BMDCs after 24 h of stimulation. 
Moreover, APCs that performed immunogenic phagocytosis can then prime CD4+ and 
CD8+ T cells and thereby trigger immunogenic T helper 1 (Th1) cell and cytotoxic T 
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lymphocyte (CTL) responses facilitating CTL-elicited cancer cell elimination through 
IFN-γ, FasL-CD95 interaction, and perforin-granzyme action (Green et al. 2009). In this 
study, primed T cells obtained after co-culture with BMDCs-ICRP-TCL caused a 
cytotoxic effect in 4T1 cells, whereas a significant increase of IFN-γ release was observed 
in the co-culture of primed T cells with 4T1 cancer cells, indicating an immune response 
against 4T1 cancer cells, which involves Th1-type cytokines. Hence, the results in this 
work strongly suggest that ICRP-mediated cell death can turn cancer cells immunogenic 
and this may promote that the cancer-immunity cycle succeed.   
 
IMMUNEPOTENT CRP is a bona fide immunogenic cell death inducer 
 
After in vitro and ex vivo evaluation of the strategies conceived to detect markers of ICD, 
the next step was to perform the gold-standard approach to detect ICD inducers which 
relies on vaccination experiments involving immunocompetent murine models and 
syngeneic cancer cells (Kepp et al. 2014). With this prophylactic tumor vaccination 
model, it was demonstrated that ICRP-TCL activates the adaptive immune system in 90% 
BALB/c mice. Usually, ICD inducers protect from 50 % to 90 % of individuals when used 
alone, without any type of adjuvants, such is the case of Hypericin-based photodynamic 
therapy (87%) (Garg et al. 2012), mitoxantrone (80%) (Menger et al. 2012), oxaliplatin 
(80%) (Tesniere et al. 2010), and nanosecond pulsed electric fields (50%) (Rossi et al. 
2019). Other treatments need two previous vaccinations to induce slower tumor growth in 
vaccinated mice (Qin et al. 2017) or the use of combinational therapy to reach protection 
in 80% of the cases (Liu et al. 2019). Moreover, agents classified as ICD inducers have 
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been studied using TCL-loaded dendritic cell vaccines, but not TCL, and after several 
vaccines boosting they reach up to 70% of survival (Chen et al. 2012).  
 
The results in this work are supported by the recent demonstration that breast tumor-
bearing mice treated with ICRP present a decrease in tumor volume and increase in 
survival in comparison with untreated mice. Also, within the tumor, ICRP treatment 
decreased PD-L1, IDO and Gal-3 expression, IL-6, IL-10, and MCP-1 levels, and 
increased IFN-γ, and IL-12 levels. Moreover, ICRP treatment increase CD8+ T cells, 
memory T cells, and innate effector cells in peripheral blood, where it was also observed 
an increase in IFN-γ, and IL-12 levels (Santana-Krímskaya et al. 2020), indicating that 
these findings could be due to ICD induction in the tumor of these mice.  
 
Recently, a list of properties of an ideal ICD inducer was proposed (Krysko et al. 2012), 
which I will discuss in regard to IMMUNEPOTENT CRP.  
 
An ideal ICD inducer:  
• Should be an efficient instigator of regulated cell death (at doses that can be used 
preclinically or clinically without substantial toxicities or side effects). ICRP 
induces regulated cell death in leukemic (Lorenzo-Anota et al. 2020), cervical 
cancer (Martínez-Torres et al. 2018), lung cancer (Martinez-Torres et al. 2019), 
and melanoma cell lines without affecting the viability of human monocytes and 
PBMCs, and murine peritoneal macrophages (Lorenzo-Anota et al. 2020; Franco-
Molina et al. 2006; Sierra-Rivera et al. 2016). In vivo, ICRP-treatment decreased 
tumor weight and improved the survival of tumor-bearing mice in a murine 
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melanoma model (Franco-Molina et al. 2010), additionally, breast tumor-bearing 
mice treated with ICRP showed a decrease in tumor volume, and increase in 
survival in comparison with untreated mice, ICRP administration decreased Ki-67 
and increased caspase-3 expression in tumor tissue, suggesting the induction of 
ICRP-mediated cancer cell death, moreover, ICRP treatment did not affect tissue 
histology of spleen, liver, kidney, brain, lung and heart of  tumor-bearing mice 
(Santana-Krímskaya et al. 2020). Furthermore, in lung and breast cancer patients 
undergoing chemotherapy or/and radiation therapy, ICRP administration resulted 
in improved life quality and immunomodulatory activity (Franco-Molina et al. 
2008; Lara et al. 2010). Thus, these results demonstrated that ICRP can be used in 
cancer patients without substantial toxicities or side effects, however it would be 
important to corroborate that ICD is taking place in cancer cells at the doses used 
clinically, it could be evaluated through the analysis of DAMPs levels in serum, 
as well as TILs, Tregs and MDSCs proportion, and CRT, RAGE, HMGB1, LC3 
and STQSM1/p62 expression within tumor microenvironment in cancer patients 
undergoing ICRP administration.  
 
• Should be capable of inducing emission of multiple types of DAMPs, TLR agonists 
and immunogenic signals. In this study it was demonstrated that ICRP treatment 
induce CRT exposure, which is an immunogenic “eat me” signal, as well as release 
of the immunogenic soluble factors ATP and HMGB1 in human and murine breast 
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cancer cells, also, in murine melanoma cells ICRP triggered CRT exposure and 
release of ATP, HSP70, HSP90 and HMGB1 (Rodríguez-Salazar et al. 2017).  
 
• Should not be subject to drug-efflux pathways. As ICRP is not a drug, is a mixture 
of substances with biological activity, it may not be subject to drug-efflux 
pathways, also, it has not been described until today mechanisms of resistance to 
ICRP-induced cell death, however, ICRP needs an overgeneration of ROS to exert 
its cytotoxic effect (Martinez-Torres et al. 2019; Martínez-Torres et al. 2018), 
thereby, antioxidants could be able to diminish its cytotoxic effects in cancer cells. 
 
• Should be capable of inducing ER stress, which would make it possible to improve 
DAMP trafficking and to increase their emission. In this work it was proved for 
the first time that ICRP induced eIF2α phosphorylation in human and murine 
breast cancer cells, which is a marker of ER stress (Kepp et al. 2015), also, in these 
cells ICRP triggers CRT exposure, that is another cellular process associated with 
ER stress (Grootjans et al. 2016). Thus, ICRP treatment induces ER stress that may 
facilitate the trafficking and emission of the DAMPs observed in this work.  
 
• Should be capable of overcoming loss-of-function mutations that cripple danger 
signaling during cancer microevolution. It has been demonstrated that ICRP 
induces apoptosis in leukemia cell lines as inhibition of caspase-3, -8 and -9 led to 
significantly cell death diminish (Lorenzo-Anota et al. 2020). However, in this 
work it was proved that ICRP treatment can overcome mutations in apoptosis 
pathway, hence, is able to induce cell death and emission of DAMPs in MCF-7 
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cells, which are caspase-3 deficient (Wang et al. 2016), and 4T1 cells, a p53 
deficient cell line (Sang et al. 2005). Moreover, ICRP induced caspase-
independent cell death in cervical (Martínez-Torres et al. 2018) and lung cancer 
cell lines (Martinez-Torres et al. 2019).  
 
• Should be capable of downregulating cancer-based induction of pro-inflammatory 
transcription factors. Activation of pro-inflammatory transcription factors such as 
NF-κB in cancer cells often correlates with increased tumor growth and a negative 
prognosis (Krysko et al. 2012). In LPS-stimulated human macrophages ICRP 
decrease IκB phosphorylation, NF-κB p50 and p65 subunit DNA binding activity 
(Franco-Molina et al. 2011), suggesting that ICRP may downregulate this pro-
inflammatory transcription factor in cancer context, however it should be 
evaluated in further studies. 
 
• Should have negligible suppressive or inhibitory effects on immune cells such as 
mature dendritic cells, natural killer cells, CD3+CD4+ T cells (mainly TH1 
phenotype), cytotoxic CD3+CD8+ T cells, memory CD3+CD4+ or CD3+CD8+ 
CD45RO+ T cells and B cells that infiltrate a tumor site following treatment, as 
they are likely to be required for immune reactions that are centered on the tumor. 
ICRP does not affect the viability of human monocytes and PBMCs, and murine 
peritoneal macrophages (Franco-Molina et al. 2006; Sierra-Rivera et al. 2016). 
Furthermore, in a recent study ICRP treatment increased the expression of the 
activation marker CD69 in PBMCs and NK cells. Also, it was observed that ICRP 
modulates NK cells, by increasing the proportion of CD56low/CD16low cells and 
 87	
the degranulation marker CD107a, suggesting a cytotoxic phenotype in these cells. 
Moreover, ICRP potentiated T cell activation in anti-CD3-pre-activated T cells, 
and decreased CD4 and CD8 expression in T cells. Also, ICRP decreased 
expression of naïve markers, and did not induce senescence or exhaustion in T 
cells (unpublished observations of our research group). In breast tumor-bearing 
mice ICRP treatment increase CD8+ T cells, memory T cells, and innate effector 
cells in peripheral blood (Santana-Krímskaya et al. 2020). Additionally, ICRP 
administration in cancer patients resulted in an increase of the total leukocytes and 
T cells subpopulations (Franco-Molina et al. 2008; Lara et al. 2010). These results 
not only indicate that ICRP has negligible suppressive or inhibitory effects on 
immune cells, but also demonstrated its favorable immunomodulatory functions. 
 
• Should be able to inhibit immune-suppressive responses, such as those mediated 
by tumor-associated macrophages (TAMs; mainly M2 phenotype), myeloid 
derived suppressor cells (MDSCs), regulatory T cells and CD3+ CD4+ T cells 
(mainly TH2 phenotype). It has been demonstrated that ICRP administration in 
breast tumor-bearing mice decreased the expression of the suppressor molecules 
PD-L1, IDO and Gal-3, however ICRP did not decrease either MDSCs nor Treg 
cells in the tumor tissue (Santana-Krímskaya et al. 2020).  
 
• Should be capable of directly targeting not only the primary tumor but also 
metastases. It is not demonstrated that ICRP directly targets metastases, however, 
in murine melanoma, ICRP decreased VEGF production in vitro and in vivo and 
prevented metastasis in tumor-bearing mice (Franco-Molina et al. 2010). In 
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addition, in a murine breast cancer model ICRP significantly decreased VEGF and 
α-SMA expression in tumor tissue as compared with untreated mice (Santana-
Krímskaya et al. 2020).  
 
Hence, IMMUNEPOTENT CRP is not only a bona fide ICD inducer, but also possess 
most of the properties of an ideal ICD inducer. It has been proposed that the induction of 
ICD eventually results in long-lasting protective antitumor immunity due to the 
“anticancer vaccine effect” (Zhou et al. 2019). Thus, I will further discuss the memory 
responses that were observed in immunized mice after prophylactic vaccinations with 
ICRP-TCL. 
 
It is known that T cell responses generally peaks ∼1-4 days after a second antigen 
stimulation (Pennock et al. 2013; Punt et al. 2019). Here, tumor-draining lymph nodes 
after three days of tumor re-challenge were analyzed. The results demonstrated a follicular 
lymphoid hyperplasia in ICRP-TCL mice, which is associated with immunological 
memory, moreover an increase of mature DCs in ICRP-TCL mice was observed in 
comparison to the naïve group. Several studies have demonstrated that effector memory 
T cells potentiate the maturation of DCs, and in addition to T cells, BCR signaling is 
sufficient for memory B cells to induce complete activation of DCs (Maddur, Kaveri, and 
Bayry 2018). Additionally, in infection diseases it has been observed that DCs isolated 
from protectively immunized mice express a memory-like behavior different from that of 
DCs isolated from non-protectively immunized mice (Hole et al. 2019), thereby, memory-
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like responses in DCs could be generated in a cancer context as well, however, it would 
be necessary to address this in future investigations. 
 
An increase of CD8+ T cells over CD4+ T cells was also demonstrated in the peripheral 
blood of immunized mice, these results correspond with the observations that in the same 
host, memory assessments result in robust CD8+ T cell responses, but poor boosting of 
CD4+ T cell recall responses (Ravkov and Williams 2009), which is correlated with the 
demonstration that CD4+ memory cells proliferated for a shorter period of time than 
CD4+ naïve cells because of their cytokine profile (MacLeod et al. 2008).  
 
Finally, tumor specific cytotoxicity by splenocytes from immunized mice was 
demonstrated, whereas no cytotoxicity was observed in the co-culture of 4T1 with 
splenocytes from naïve mice, indicating the activation of a rapid immune response 
triggered by the antitumor memory establishment. These evaluations correspond with the 
ex vivo assessment performed in this investigation, where it was observed an increase in 
Th1-type cytokines, which are associated with cytotoxic responses generation (Berger 
2000).  
 
Therapeutic potential of tumor cell lysates obtained by ICRP treatment 
 
As a confirmatory assay, ICRP-TCL was assessed for their ability to mediate immune 
system-dependent therapeutic effects against established neoplastic lesions, in this 
scenario tumor cell lysates obtained by bona fide ICD inducers treatment mediate optimal 
therapeutic effects in immunocompetent mice. The results presented in this work 
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demonstrate that ICRP-TCL induced tumor regression and increase survival in 4T1-tumor 
bearing mice, that confirms the immune response triggered by ICRP-TCL against 4T1 
cells, leading to tumor eradication.  
  
Moreover, it is important to mention that whole tumor cell lysates have been proposed as 
a therapeutic approach in cancer therapy. There are several clinical trials using tumor cell 
lysates as immunogenic sources for cancer vaccine design, for instance, there is a study in 
phase I/II for subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer 
to determine the immunogenicity of an autologous Oxidized tumor Cell Lysate (OC-L) 
administered in combination with a Toll-like receptor 3 agonist (NCT01312389), also, a 
phase II trial studies the effectiveness of autologous tumor cell vaccination plus 
immunologic adjuvant (GM-CSF) in treating patients who have metastatic cancer 
(NCT00002505), and another study uses resected tumor cells irradiated and mixed with 
CpG to create a vaccine (NCT00780988). In other clinical trials tumor cell lysates are 
used to pulse DCs, for example, a study in early phase I investigates the safety and efficacy 
of dendritic cells vaccines pulsed with autologous whole tumor cell lysate for treating 
advanced solid tumor patients with high tumor mutation burden (NCT03671720). The 
majority of these studies are based on models performed in mice, where most of them use 
tumor cell lysates in combination with adjuvants to reach a therapeutic success (Kawahara 
and Takaku 2015; Pyo et al. 2016; Si et al. 2017). Here, tumor regression in 88% of mice 
treated with ICRP-TCL was obtained without any type of adjuvants.  
 
The four common whole tumor lysate preparations are obtained by the treatment of cancer 
cells with hypochlorous acid (HOCl), ultra-violet B (UVB)-irradiation, repeated freeze-
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thaw, and hyperthermia. These treatments can induce the release of tolerogenic and 
immunogenic signals from cancer cells that could promote a tolerogenic transformation 
of DCs. Therefore, a whole tumor lysate preparation that simultaneously induces an 
immunogenic cell death and suppress the release immunosuppressive signals from the 
tumor cells would be highly desirable (Chiang, Coukos, and Kandalaft 2015). The 
findings in this work allow to propose the evaluation of tumor cell lysates obtained by 
ICRP treatment as an immunotherapy approach in cancer treatment, also these results 
strongly suggest that dendritic cells vaccines pulsed with ICRP-TCL may be a promising 
strategy for cancer therapy.  
 
IMMUNEPOTENT CRP in the landscape of cancer therapy 
 
In the past 25 years, research efforts in cancer therapy has largely addressed two lines of 
inquiries, one focused on the development of targeted agents that result in profound, but 
often not durable, tumor responses in genetically defined patient populations, and another 
approach looking for protected anticancer immunity to accomplish durable clinical 
responses. In this regard, immunity is influenced by a complex set of host, environment, 
and tumor factors that dictates the strength and timing of the anticancer response (Gotwals 
et al. 2017). These investigations led to the definition of the cancer–immune set point that 
can be understood as a balance between the stimulatory factors minus the inhibitory 
factors, which together must be equal to or greater than 1, over the summation of all T-
cell antigen receptor (TCR) signals for tumor antigens (Chen and Mellman 2017). In this 
aspect, direct stimulation of immune cell or the induction of immunogenic cell death in 
cancer cells could alter the set point, for example, by propagating the cancer-immunity 
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cycle, which enhances the cancer-specific T-cell response. Thereby, IMMUNEPOTENT 
CRP, is a promising therapy, as it can induce immunomodulatory effects and eject ICD 
on breast cancer cells.  
 
To this day, only a few therapies induce the immunogenic demise of cancer cells, and 
several studies indicate that ICD-inducing chemotherapy can initiate robust anticancer 
immunity increasing the efficacy of the treatment (Garg et al. 2017). Withal, as a negative 
aspect, the widespread use of chemotherapy has been implemented mostly on empirical 
(rather than immunological) grounds, thus, possible scenarios of chemotherapeutic action 
on the cancer–host relationship are immunosuppressive adverse effects and selection of 
therapy-resistant and immune-resistant cancer cells, thereby, one of the goals in cancer 
therapy is  to identify doses and administration schedules that mediate maximal 
immunostimulatory effects (Zitvogel, Kepp, and Kroemer 2011).  
 
In this regard, in 2016, Coronado-Cerda et al. observed that ICRP has a chemo-protective 
effect in bone marrow cells exposed to 5-FU (Coronado-Cerda et al. 2016). In addition, 
Rodríguez-Salazar et al. demonstrated that ICRP in combination with oxaliplatin (OXP) 
increased the exposure and release of DAMPs, moreover, administration of TCL derived 
from B16F10 cells treated with ICRP + OXP prevented melanoma growth in mice; 
whereas, TCL obtained from B16F10 cells treated with OXP did not protect from tumor 
growth (Rodríguez-Salazar et al. 2017). Recently, Santana-Krímskaya et al. observed that 
ICRP administration in 4T1-tumor bearing mice treated with doxorubicin and 
cyclophosphamide potentiates the anti-tumor effect of Dox/Cyclo chemotherapy, and 
modifies the tumor microenvironment decreasing the immune-suppression consequences 
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triggered by the administration of these chemotherapeutic agents (Santana-Krímskaya et 
al. 2020). Furthermore, in 2010 Lara et al. carried out a study in breast cancer patients 
receiving chemotherapy and ICRP as adjuvant. The results showed that 60% of the 
patients in the group receiving ICRP as adjuvant displayed a complete response, 32% 
showed a partial response and 8% did not respond. By contrast, in the group without the 
adjuvant, 39% showed a complete response, 50% displayed a partial response and 11% 
were non-responders. In addition, ICRP treatment in combination with chemotherapy 
resulted in quality of life enhancement during chemotherapy (Lara et al. 2010).  Overall, 
observations in this study and previous data discussed above, propose the use of ICRP to 
optimize chemotherapy schedule.  
 
Furthermore, along with the hurdle mentioned above, cancer is an evolving disease, and 
some cancer cells display alterations that prevent the activation of tumor-targeting 
immunity triggered by malignant cells undergoing ICD. This constitutes a major obstacle 
to the efficacy of ICD-inducing therapies, thereby is urgent the development of efficacious 
combinatorial regimens (Wu and Waxman 2018), thus, application of IMMUNEPOTENT 
CRP could have a pivotal effect by stimulating immune cells, and inducing ICD in cancer 






Overall, there results demostrate that IMMUNEPOTENT-CRP triggers an endoplasmic 
stress accompanied by the increase of cytoplasmic Ca2+ levels. Ca2+ entry to cancer cells 
leads to mitochondrial damage, ROS production, and CRT exposure. This intracellular 
signaling pathway promotes autophagosome formation and the release of ATP and 
HMGB1, which along with CRT exposure stimulate DCs maturation, priming of T cells, 
promoting an antitumor immune response ex vivo. Prophylactic vaccination with ICRP-
TCL prevents tumor establishment in BALB/c mice leading to a long-term antitumor 
memory that involves DCs maturation in lymph nodes, CD8+ T-cells augmentation in 
peripheral blood, and ex vivo tumor-specific cytotoxicity by splenocytes. Moreover, 
therapeutic vaccinations with ICRP-TCL generate tumor regression in 4T1-tumor bearing 
mice, triggering long-term antitumor memory in treated mice. Hence, ICRP may have the 
capacity to turn breast cancer cells into potential vaccines in vivo through the induction of 





• Elucidate Ca2+ signaling differences between normal cells and malignant cells 
treated with ICRP. 
• Study Ca2+ signaling in the activation of immune cells triggered by ICRP. 
• Investigate the nexus between Ca2+ deregulation and immunogenicity of ICRP-
induced cell death in cancer cells.  
• Evaluate Ca2+ levels in subcellular organelles (such as mitochondria and 
endoplasmic reticulum) in cancer cells treated with ICRP.  
• Elucidate the role of mitochondrion-associated membranes of endoplasmic 
reticulum in ICRP-mediated cell death.  
• Study the implication of autophagosome formation in the immunogenicity of 
ICRP-induced cell death.  
• Evidence the mechanism of DAMPs release triggered by ICRP.  
• Determinate the anti-tumor potential of ICRP treatment in immunodeficient mice, 
as ICD-eliciting agents must exhibit superior therapeutic efficacy when employed 
against tumors growing in immunocompetent mice as compared to 
immunodeficient hosts.  
• Investigate the therapeutic potential of ICRP-TCL-loaded dendritic cell vaccines, 
with murine and human dendritic cells. 
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